[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 37376
1. Adams H, Tzankov A, d'Hondt S, Jundt G, Dirnhofer S, Went P: Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. Hum Pathol; 2008 Sep;39(9):1323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
  • Diffuse large B-cell lymphomas can be considered primary bone tumors if they are monostotic or polyostotic, affecting multiple skeletal sites without visceral or lymph node involvement.
  • They are rarely considered as extranodal lymphomas or as bone tumors, respectively.
  • To elucidate the prognostic relevance of clinicopathologic characteristics in such disease, we collected a cohort of primary diffuse large B-cell lymphomas of the bone and retrospectively investigated 33 patients.
  • Disease stage was I and II in 30 and IV in 3 patients.
  • Clinical factors favoring a good prognosis were age younger than 53 and administration of chemotherapy.
  • Of the phenotypic markers analyzed (CD10, CD44s, CD138, Bcl-2, Bcl-6, MUM1, and Ki-67), MUM1 expression in more than 10% of the tumor cells and CD10 expression in less than 55% as well as a nongerminal center signature substantiated adverse outcome in a univariate model.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Child, Preschool. Cohort Studies. Female. Gene Expression. Gene Rearrangement, B-Lymphocyte. Humans. In Situ Hybridization, Fluorescence. Interferon Regulatory Factors / biosynthesis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Proto-Oncogene Proteins c-bcl-2 / genetics. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614198.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4
  •  go-up   go-down


2. Michel RB, Andrews PM, Rosario AV, Goldenberg DM, Mattes MJ: 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl Med Biol; 2005 Apr;32(3):269-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
  • Antibodies (Abs) conjugated to 177Lu, a relatively low-energy beta-particle emitter, were evaluated in vitro for their cytotoxic activity and in vivo for their therapeutic activity against disseminated B-cell lymphoma xenografts in SCID mice.
  • The Abs used reacted with CD20, CD74 or HLA-DR, and the target cell was the Raji B lymphoma.
  • It appeared to be slightly less potent than (131)I per decay, but this difference was relatively small, and would not be a major factor in the selection of the optimal radionuclide for clinical use.
  • [MeSH-major] Antibodies / therapeutic use. Cell Survival / radiation effects. Lutetium / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Radioisotopes / therapeutic use
  • [MeSH-minor] Animals. Body Burden. Cell Line, Tumor. Dose-Response Relationship, Radiation. Lymphatic Metastasis. Mice. Mice, SCID. Radiation Dosage. Radiometry. Radiopharmaceuticals / therapeutic use. Relative Biological Effectiveness. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820762.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA87059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 5H0DOZ21UJ / Lutetium
  •  go-up   go-down


3. Asano N, Yamamoto K, Tamaru J, Oyama T, Ishida F, Ohshima K, Yoshino T, Nakamura N, Mori S, Yoshie O, Shimoyama Y, Morishima Y, Kinoshita T, Nakamura S: Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood; 2009 Mar 19;113(12):2629-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients.
  • Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder (aEBVLPD) is a disease group characterized by EBV-associated large B-cell lymphoma in elderly without predisposing immunodeficiency.
  • In nearly one- third of cases, aEBVLPD occurs as a polymorphous subtype with reactive cell-rich components, bearing a morphologic similarity to classic Hodgkin lymphoma (cHL).
  • The aim of this study was to clarify clinicopathologic differences between the polymorphic subtype of aEBVLPD (n = 34) and EBV(+) cHL (n = 108) in patients aged 50 years or older.
  • Results showed that aEBVLPD was more closely associated with aggressive clinical parameters than cHL, with a higher age at onset (71 vs 63 years); lower male predominance (male-female ratio, 1.4 vs 3.3); and a higher rate of involvement of the skin (18% vs 2%), gastrointestinal tract (15% vs 4%), and lung (12% vs 2%).
  • aEBVLPD was histopathologically characterized by a higher ratio of geographic necrosis, greater increase (> 30%) in cytotoxic T cells among background lymphocytes, higher positivity for CD20 and EBNA2, and absence of CD15 expression.
  • As predicted by the clinical profile, aEBVLPD had a significantly poorer prognosis than EBV(+) cHL (P < .001).
  • The polymorphous subtype of aEBVLPD constitutes an aggressive group with an immune response distinct from EBV(+) cHL, and requires the development of innovative therapeutic strategies.
  • [MeSH-major] Aging / immunology. Epstein-Barr Virus Infections / epidemiology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075188.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


Advertisement
4. Mercer SE, Vidal CI, Grummer SE, Strauchen JA, Gordon ML, Birge MB: Pagetoid reticulosis after radiotherapy of primary cutaneous anaplastic large-cell lymphoma. Am J Dermatopathol; 2010 Feb;32(1):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pagetoid reticulosis after radiotherapy of primary cutaneous anaplastic large-cell lymphoma.
  • We describe a 60-year-old man with a history of primary cutaneous anaplastic large cell lymphoma on the chest, who presented with a new scaly red plaque on the same site 11 years after radiation therapy.
  • Histological examination revealed a dense epidermotropic infiltrate of atypical mononuclear cells consistent with pagetoid reticulosis.
  • Remarkably, all the atypical cells were strongly CD30, and furthermore, the CD30 cells were found exclusively in the epidermis.
  • In the initial cutaneous anaplastic large cell lymphoma lesion, the CD4, CD8, and focally CD30 atypical cells were well confined within the dermis with no epidermal component.
  • To our knowledge, the present case seems to be the first description of pagetoid reticulosis presenting at the site of a previously treated dermal anaplastic large cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / radiotherapy. Neoplasms, Second Primary / pathology. Pagetoid Reticulosis / pathology. Skin Neoplasms / pathology. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940753.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Cocco P, Brennan P, Ibba A, de Sanjosé Llongueras S, Maynadié M, Nieters A, Becker N, Ennas MG, Tocco MG, Boffetta P: Plasma polychlorobiphenyl and organochlorine pesticide level and risk of major lymphoma subtypes. Occup Environ Med; 2008 Feb;65(2):132-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma polychlorobiphenyl and organochlorine pesticide level and risk of major lymphoma subtypes.
  • BACKGROUND: There is conflicting epidemiological evidence concerning an increase in risk of non-Hodgkin's lymphoma (NHL) associated with elevated blood levels of persistent organochlorine (OC) pesticides and polychlorobiphenyls (PCBs).
  • RESULTS: Risk of NHL, diffuse large B cell lymphoma (DLBCL) and chronic lymphatic leukaemia (CLL) did not increase with plasma levels of HCB, beta-HCH, p,p'-dichloro-diphenyl-dichloroethylene (DDE), or total and individual PCBs or their functional groups, in the overall study population.
  • [MeSH-major] Environmental Pollutants / blood. Hydrocarbons, Chlorinated / blood. Lymphoma, Non-Hodgkin / blood. Pesticide Residues / blood. Polychlorinated Biphenyls / blood
  • [MeSH-minor] Adult. Case-Control Studies. Female. France. Germany. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Logistic Models. Lymphoma, Large B-Cell, Diffuse / blood. Male. Middle Aged. Odds Ratio. Risk Assessment / methods. Spain

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699548.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticide Residues; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


6. Wada N, Ham MF, Fujita S, Shimazu H, Kurniawan AN, Hardjolukito ES, Suzanna E, Jia XS, Yang WI, Aozasa K: Malignant lymphomas in Waldeyer's ring in Asian countries: Association with histologic types and Epstein-Barr virus. Mol Med Rep; 2008 Sep-Oct;1(5):651-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphomas in Waldeyer's ring in Asian countries: Association with histologic types and Epstein-Barr virus.
  • The present study examines clinicopathologic findings and their association with the Epstein-Barr virus (EBV) in Waldeyer's ring lymphomas (WRLs) from Indonesia (91 cases), P.R.
  • Diffuse large B-cell lymphoma (DLBCL) pre-dominated in the lower WR in all countries at a frequency of 78.9-100%.
  • Natural killer/T-cell lymphoma (NKTCL) was predominant in the upper WR in China, Korea and Japan at a frequency of 50-62.5%, while in Indonesia it occcurred at a frequency of less than 10%.
  • This study evaluates the differences between East and Southeast Asian countries in terms of histologic type and age distribution in WRLs categorized by the location of the lesions in WR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479464.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Wobser M, Voigt H, Eggert AO, Houben R, Kauczok CS, Bröcker EB, Becker JC: Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer; 2007 May 21;96(10):1540-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma.
  • Rituximab has been established as an effective and safe therapy for cutaneous B-cell lymphoma (CBCL).
  • Biopsies from four patients, suffering from different subtypes of CBCL, which were obtained at various time points of relapse during or after therapy with 375 mg rituximab per m2 of body surface area, were analysed for the expression of CD20, CD3, Ki-67, Raf-kinase inhibitory protein (RKIP) and bcl-2 by immunohistochemistry.
  • However, relapsing CBCL exhibited a strong upregulation of the antiapoptotic molecule bcl-2 in comparison to pretherapeutic levels.
  • The immunohistochemical analyses of this case series of rituximab refractory CBCL suggest that upregulation of bcl-2 may play a major role in therapy resistance.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Drug Resistance, Neoplasm / genetics. Genes, bcl-2. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2001 May-Jun;24(3):263-71 [11394505.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):881-3 [11564080.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1619-26 [11587221.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1147-58 [12452864.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2934-49 [15077155.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3530-40 [15077178.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Cell Biochem. 2005 Feb 1;94(2):273-8 [15565643.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2507-13 [12446458.001]
  • (PMID = 17473827.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / PEBP1 protein, human; 0 / Phosphatidylethanolamine Binding Protein; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2359948
  •  go-up   go-down


8. Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM: Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys; 2009 May 1;74(1):154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.
  • PURPOSE: To determine the efficacy of low-dose palliative radiotherapy for both low-grade malignant cutaneous B-cell lymphomas (CBCLs) and cutaneous T-cell lymphomas (mycosis fungoides).
  • METHODS AND MATERIALS: A total of 18 patients with low-grade CBCL (10 primary cutaneous marginal zone B-cell and 8 primary cutaneous follicle center lymphomas) with 44 symptomatic plaques and tumors underwent low-dose (4 Gy in two fractions) local radiotherapy.
  • Of the 44 B-cell lymphoma lesions, 13 were re-treated to the same site after a median of 6.3 months because of persistent (n = 8) or recurrent (n = 5) symptomatic disease.
  • CONCLUSION: Our results have demonstrated that low-dose involved-field radiotherapy induces a high response rate in both CBCL and cutaneous T-cell lymphoma lesions without any toxicity.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Cutaneous / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Male. Middle Aged. Mycosis Fungoides / pathology. Mycosis Fungoides / radiotherapy. Radiotherapy Dosage. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834672.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, Gascoyne RD, Gordon LI: Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol; 2010 Feb 20;28(6):1017-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.
  • We previously showed constitutive stabilization of HIF-1alpha in the majority of patients with diffuse large B-cell lymphoma (DLBCL).
  • To our knowledge, the prognostic significance of HIF in lymphoma has never been investigated.
  • Among all patients, HIF-1alpha was expressed in 62% of germinal center and 59% of non-germinal center patients.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3773-80 [19029441.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2000;35(2):71-103 [10821478.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3995-4004 [11359907.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38205-11 [12149254.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8948-51 [14654791.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23757-63 [8089148.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1129-35 [15709180.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Dec;1(2):104-11 [16264828.001]
  • [Cites] Histopathology. 2006 Feb;48(3):258-67 [16430472.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4207-13 [16449523.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7369-73 [17189409.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):230-8 [17785204.001]
  • [Cites] Lab Invest. 2008 Jan;88(1):38-47 [17998899.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Free Radic Biol Med. 2008 Feb 15;44(4):614-23 [18060882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4745-50 [18347341.001]
  • [Cites] Br J Haematol. 2008 May;141(5):676-80 [18422776.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5509-14 [18445689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):967-75 [18987634.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Hematol Oncol. 2008 Dec;26(4):219-24 [18461646.001]
  • [Cites] J Appl Physiol (1985). 2000 Apr;88(4):1474-80 [10749844.001]
  • (PMID = 20048181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109613-05; United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / K23 CA109613-A1; United States / NCI NIH HHS / CA / K23 CA109613-05; United States / NCI NIH HHS / CA / K23 CA109613-04; United States / NCI NIH HHS / CA / CA109613-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2834428
  •  go-up   go-down


10. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH, Groupe d'étude des lymphomes de l'adulte: Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol; 2007 Jul;18(7):1209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
  • BACKGROUND: Lymphocytopenia is a prognostic factor in Hodgkin's disease.
  • In diffuse large B-cell lymphoma (DLBCL), data are much less established, in spite of numerous reports on immune system-lymphoma interactions.
  • This study addresses the prognostic value of blood lymphocyte subsets at diagnosis in DLBCL.
  • PATIENTS AND METHODS: Absolute values of blood lymphocyte subsets and monocytes were prospectively determined by flow cytometry in 140 patients with 2 or 3 adverse age-adjusted International Prognostic Index (aaIPI) factors included in a Groupe d'Etude des Lymphomes de l'Adulte protocol (LNH98B3).
  • Absolute cell counts at diagnosis and aaIPI were evaluated with regard to clinical outcome.
  • RESULTS: Low median cell counts of 337, 211, and 104/mul were evidenced for the CD4+, CD8+ T, and natural killer (NK) cells, respectively.
  • In univariate analysis, only NK cell count [odds ratio (OR) = 1.81 (1.27, 2.57), P = 0.001] and aaIPI [OR = 2.29 (0.95, 5.45), P = 0.06] were associated with induction treatment response.
  • Low NK cell count [Hazard ratio (HR) = 1.27 (1.06, 1.52), P = 0.01] and aaIPI 3 [HR = 1.95 (1.20, 3.16), P = 0.01] were also associated with a shorter event free survival (EFS).
  • In multivariate analysis, NK cell count was associated with response [OR = 1.77 (1.24, 2.54), P = 0.002] and EFS [HR = 1.25 (1.04, 1.50) P = 0.02] independently of aaIPI.
  • CONCLUSIONS: This study shows an association between circulating NK cell number and clinical outcome in DLBCL, possibly important in the context of the broadening use of rituximab, a likely NK-dependent therapy.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496307.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


11. Ng TG, Ayadurai K, Gangaram HB, Hussein SH: Subcutaneous panniculitic T-cell lymphoma-review of five cases. Med J Malaysia; 2006 Dec;61(5):586-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitic T-cell lymphoma-review of five cases.
  • Subcutaneous panniculitic T-cell lymphoma (SPTL) is a rare variant of cutaneous T-cell lymphoma where lymphoma cells infiltrate preferentially into subcutaneous tissue.
  • Skin biopsy of all patients showed infiltration with atypical lymphoid cells in the upper dermis and subcutaneous fat.
  • These neoplastic cells showed positivity for CD3 and CD30 in three patients with CD8, TIA-1 and LCA (Leucocyte common antigen) being positive in one patient.
  • Subcutaneous panniculitic T-cell lymphoma has been reported to show two distinct clinical presentations.
  • The first is characterized by an indolent course with good prognosis and the second with rapid clinical deterioration, haemophaegocytosis and death.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / diagnosis. Panniculitis / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17623960.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


12. Abd El-Rahman H, Bedair RM: Treatment Outcome of Pediatric Patients with Mature B Cell Lymphoma Receiving Fab LMB96 Protocol at the National Cancer Institute, Cairo University. J Egypt Natl Canc Inst; 2010 Dec;22(4):201-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment Outcome of Pediatric Patients with Mature B Cell Lymphoma Receiving Fab LMB96 Protocol at the National Cancer Institute, Cairo University.
  • INTRODUCTION: Lymphomas are the third most common malignant tumor in the pediatric age group after leukemia and brain tumors.
  • Outcome has improved remarkably over the past decade because of improvements in imaging and staging systems that more accurately reflect the clinical behavior, and the development of risk adapted multiagent chemotherapeutic regimens.
  • The aim of this work is to study the outcome, Overall Survival (OS) and Event Free Survival (EFS) of patients receiving FAB LMB96 protocol applied for treatment of mature B cell lymphoma.
  • PATIENTS AND METHODS: This is a retrospective study analyzing the data of 103 newly diagnosed pediatric NHL [Burkitt's lymphoma÷leukemia, Diffuse Large B Cell Lymphoma (DLBCL)] who received LMB96 protocol at Department of Pediatric Oncology, National Cancer Institute, Cairo University, during the time period from 1st of January 2006 to the end of December 2008.
  • Abdominal presentation was the most common clinical presentation seen in 85 patients (82.5%) followed by thoracic mass in 27 patients (26.2%) and cervical mass in 22 patients (21.4%).
  • The most common pathological subtype was Burkitt's lymphoma seen in 83 patients (80.6%) followed by DLBCL in 12 patients (11.7%).
  • The commonest treatment group seen was group B in 80 patients (77.7%) followed by group C in 19 patients (18.4%) then group A in 4 patients (3.9%).Complete remission for the whole group of patients was achieved in 72 patients (70%), relapses and disease progression occurred in 9 patients (8.7%) and stable disease in 1 patient (1%).
  • KEY WORDS: NHL- FAB LMB96- Pediatric- Lymphoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21863071.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


13. Grubstein A, Givon-Madhala O, Morgenstern S, Cohen M: Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis. J Clin Ultrasound; 2005 Mar-Apr;33(3):140-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis.
  • We report a case of primary, high-grade non-Hodgkin B-cell lymphoma in the breast of a young woman.
  • The clinical and sonographic presentation was not of a mass but of an infiltrating anechoic process mimicking mastitis.
  • Primary breast lymphoma is a rare entity, especially in young females.
  • In previous imaging reports of breast lymphoma, it has always been considered as a mass, though the presence of markedly hypoechoic regions that look like fluid collections is a well known sonographic characteristic of lymphoma.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography. Mastitis / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Mammary


14. Sniderhan LF, Garcia-Bates TM, Burgart M, Bernstein SH, Phipps RP, Maggirwar SB: Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma. Exp Hematol; 2009 Nov;37(11):1295-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma.
  • In order to analyze the potential contribution of neurotrophin signaling to lymphoma cell survival, we investigated the role of a neurotrophin axis in promoting survival and proliferation of non-Hodgkin lymphoma (NHL) cells.
  • MATERIALS AND METHODS: The role of neurotrophins in the survival and proliferation of NHL cells was determined by exposing cells to the Trk-specific inhibitor, K252a, and then performing (3)H-thymidine incorporation and Annexin-V/propidium iodide staining.
  • RESULTS: Here we demonstrate that both primary NHL cells and diffuse large B-cell lymphoma cell lines express Trk receptors and their neurotrophin ligands.
  • Furthermore, these cells are sensitive to the Trk-specific inhibitor, K252a, as evidenced by the inhibition of proliferation and/or induction of apoptosis.
  • Analysis of the mechanism into the effects of K252a revealed that, in the OCI-LY3 cell line, K252a induced a subnuclear distribution of NF-kappaB resulting in the sequestration of RelA in the nucleolus, thereby inhibiting NF-kappaB-dependent gene transcription.
  • This results in the loss of interleukin-6 production; a known survival-promoting signal for OCI-LY3, as well as many primary diffuse large B-cell lymphomas.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 1997 Aug;77(2):161-73 [9258246.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1887-98 [9717816.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):865-70 [10049950.001]
  • [Cites] Cancer Invest. 1999;17(6):391-5 [10434949.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Am J Transplant. 2005 Jan;5(1):76-86 [15636614.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] EMBO J. 2005 Mar 23;24(6):1157-69 [15775976.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):141-3 [15944781.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] Eur J Neurosci. 2006 May;23(10):2623-34 [16817865.001]
  • [Cites] Mol Cell Biochem. 2007 Jan;295(1-2):19-26 [16862449.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1660-9 [17308107.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12619-28 [17337442.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Cell Cycle. 2007 Jun 1;6(11):1293-7 [17525529.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(16):5686-98 [17548467.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7012-21 [18056177.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1360-7 [17786033.001]
  • [Cites] Dev Neurobiol. 2008 Mar;68(4):457-75 [18172890.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):749-53 [18288411.001]
  • [Cites] J Biol Chem. 2008 Jun 6;283(23):15799-806 [18381284.001]
  • [Cites] J Neurosci. 2008 Sep 24;28(39):9857-69 [18815270.001]
  • [Cites] Neurochem Res. 2009 May;34(5):942-51 [18846424.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jan;132(1):118-24 [18181663.001]
  • [Cites] Eur Cytokine Netw. 2000 Jun;11(2):283-91 [10903808.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):753-9 [11095980.001]
  • [Cites] Eur J Immunol. 2002 Jan;32(1):136-43 [11754354.001]
  • [Cites] Curr Opin Cell Biol. 2003 Jun;15(3):304-10 [12787772.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4649-62 [12808104.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1948-60 [14513044.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):370-80 [14688345.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19893-901 [14976189.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S41-7 [15202524.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3615-24 [15252129.001]
  • [Cites] J Antibiot (Tokyo). 1986 Aug;39(8):1059-65 [3759657.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1986;51 Pt 2:983-92 [3472772.001]
  • [Cites] Blood. 1989 Aug 1;74(2):798-804 [2787680.001]
  • [Cites] Cell. 1991 Jul 12;66(1):173-83 [1649007.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):13-6 [1730579.001]
  • [Cites] Oncogene. 1992 Feb;7(2):371-81 [1312698.001]
  • [Cites] Biochemistry. 1993 May 4;32(17):4650-8 [7683492.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10984-8 [7902578.001]
  • [Cites] J Neuroimmunol. 1996 Feb;64(2):141-9 [8632056.001]
  • [Cites] J Neurosci. 1996 May 1;16(9):2995-3008 [8622129.001]
  • [Cites] Cell. 1996 May 3;85(3):345-56 [8616890.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2443-9 [8630409.001]
  • [Cites] Eur J Immunol. 1996 Sep;26(9):1985-92 [8814235.001]
  • [Cites] J Androl. 1996 Sep-Oct;17(5):481-90 [8957691.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):49-55 [9049830.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20490-4 [9252360.001]
  • (PMID = 19716854.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS054578; United States / NIDCR NIH HHS / DE / DE011390; United States / NIAID NIH HHS / AI / T32 AI049815; United States / NIEHS NIH HHS / ES / ES01247; United States / NIEHS NIH HHS / ES / P30 ES001247; United States / NINDS NIH HHS / NS / R01 NS054578-04; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NIDCR NIH HHS / DE / R01 DE011390; United States / NINDS NIH HHS / NS / R01 NS066801; United States / NINDS NIH HHS / NS / NS054578-04; United States / NIAID NIH HHS / AI / T32 AI49105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AG-879; 0 / Brain-Derived Neurotrophic Factor; 0 / Carbazoles; 0 / Culture Media, Conditioned; 0 / Indole Alkaloids; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Nerve Growth Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Nerve Growth Factor; 0 / Tyrphostins; 9061-61-4 / Nerve Growth Factor; 97161-97-2 / staurosporine aglycone
  • [Other-IDs] NLM/ NIHMS142460; NLM/ PMC2772191
  •  go-up   go-down


15. Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N, Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS): Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study. Biol Blood Marrow Transplant; 2010 May;16(5):672-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
  • To evaluate the effect of rituximab in poor-prognosis patients with diffuse large B-cell lymphoma (DLBCL), a multicenter phase II trial combining rituximab with chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplant was conducted by the Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS).
  • For patients who achieved at least a partial remission (PR), HDT followed by autologous stem cell transplant was performed on day 66.
  • First-line HDT with rituximab offers promising results for young adults with intermediate high or high aa-IPI high-grade lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Remission Induction. Risk Factors. Rituximab. Survival Rate. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20045738.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R, Enblad G: Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol; 2005 Aug;18(8):1113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis.
  • Diffuse large B-cell lymphoma (DLBCL) has been shown to be comprised of at least two prognostic entities, depending on its resemblance to normal germinal center or activated B cells, using global gene expression profiling.
  • Also, the expression patterns of bcl-6, CD10 and IRF-4 (also known as MUM1) have been suggested as alternative means of identifying the germinal- and nongerminal center (activated B-cell like) groups.
  • In the present study, we evaluated by immunohistochemistry the expression patterns of CD10, bcl-6, IRF-4 and bcl-2 in a large material of 161 DLBCL patients.
  • Positive staining for bcl-6 or CD10 predicted for superior survival, while expression of IRF-4 alone showed no association with prognosis.
  • Furthermore, expression of bcl-2 was associated with worse event-free survival and overall survival.
  • In a multivariate analysis, a high international prognostic index score (3-5), non-GC phenotype and bcl-2 were independent adverse prognostic factors.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA-Binding Proteins / analysis. Female. Germinal Center / pathology. Humans. Immunohistochemistry. Interferon Regulatory Factors. Male. Middle Aged. Models, Biological. Multivariate Analysis. Neprilysin / analysis. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Survival Analysis. Transcription Factors / analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920553.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


17. Ikonomou IM, Aamot HV, Heim S, Fosså A, Delabie J: Granulomatous slack skin with a translocation t(3;9)(q12;p24). Am J Surg Pathol; 2007 May;31(5):803-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulomatous slack skin is a rare cutaneous T-lymphoproliferative disease characterized by pendulous skin folds.
  • Histology typically reveals a dermal infiltrate of T cells and multinucleated giant cells showing elastophagocytosis.
  • We present a well-documented case of a 46-year-old man with the typical histologic and clinical findings of granulomatous slack skin.
  • Cytogenetic analysis of a skin biopsy revealed a t(3;9)(q12;p24) as the sole chromosomal abnormality.
  • Fluorescence in situ hybridization analysis did not reveal involvement of the JAK2 gene, located at chromosome band 9p24, and previously shown to be amplified in Hodgkin lymphoma and primary mediastinal diffuse large B-cell lymphoma.
  • Although more cases have to be reported and the putative oncogene involved in the translocation has yet to be identified, the cytogenetic findings are unlike those described for mycosis fungoides and suggests that granulomatous slack skin is a distinct primary cutaneous T-cell lymphoma.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. Gene Rearrangement / genetics. Genes, T-Cell Receptor gamma / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460466.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Ferry JA, Sohani AR, Longtine JA, Schwartz RA, Harris NL: HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma. Mod Pathol; 2009 May;22(5):618-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma.
  • Human herpesvirus type 8 (HHV8), also known as Kaposi's sarcoma-associated herpesvirus, is a human gamma herpesvirus that underlies the pathogenesis of Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease.
  • We recently encountered two cases of HHV8-positive large B-cell lymphoma with features not previously described.
  • The first patient was a 61-year-old immunocompetent man with an enlarged cervical lymph node containing scattered large, bizarre cells in a reactive background of lymphocytes, plasma cells and scattered regressed follicles resembling those of hyaline-vascular Castleman's disease.
  • The appearance suggested classical Hodgkin's lymphoma, but the large cells were negative for CD15, CD30, CD20 and CD3, and positive for MUM1/IRF4, EMA, HHV8, EBER and dim IgM lambda.
  • At autopsy an intravascular large B-cell lymphoma that was positive for MUM1/IRF4, HHV8 and IgM lambda, and negative for CD20 and EBER involved multiple organs, including lung, heart, kidney, liver and spleen.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesviridae Infections / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287457.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tilly H, Dreyling M, ESMO Guidelines Working Group: Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol; 2008 May;19 Suppl 2:ii67-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456774.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


20. Aster J, Kutok J: Complexity made simple in diffuse large B-cell lymphoma. Clin Cancer Res; 2009 Sep 1;15(17):5291-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complexity made simple in diffuse large B-cell lymphoma.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3383-5 [16091454.001]
  • [Cites] Histopathology. 2006 Oct;49(4):406-10 [16978204.001]
  • [Cites] Histopathology. 2006 Oct;49(4):411-24 [16978205.001]
  • [Cites] Oncologist. 2008 May;13(5):477-93 [18515733.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5494-502 [19706817.001]
  • [CommentOn] Clin Cancer Res. 2009 Sep 1;15(17):5494-502 [19706817.001]
  • (PMID = 19706818.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092625-019002; United States / NCI NIH HHS / CA / P01 CA092625; United States / NCI NIH HHS / CA / P01 CA092625-019002
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / FOXP1 protein, human; 0 / Forkhead Transcription Factors; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / Repressor Proteins; 0 / SERPINA9 protein, human; 0 / Serpins; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ NIHMS131780; NLM/ PMC2737086
  •  go-up   go-down


21. Harket A, Oukabli M, Al Bouzidi A, Zoubeir Y, Quamous O, Baba N, Doghmi K, Mikdame M, Rimani M, Sedrati O, Labraimi A: [Cutaneous blastomycosis revealing intravascular B-cell lymphoma: a case in Morocco]. Med Trop (Mars); 2007 Jun;67(3):278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous blastomycosis revealing intravascular B-cell lymphoma: a case in Morocco].
  • [Transliterated title] Blastomycose cutanée révélant un lymphome B intravasculaire: une observation marocaine.
  • Biopsy of one nodules showed a pseudoepitheliomatous hyperplastic epidermis overlaying a dense agranulomatous inflammatory infiltrate containing free-formed ovoid bodies enclosing giant macrophageous cells.
  • Needle liver biopsy revealed giant B-cell lymphomatous infiltration of the hepatic ducts.
  • The patient's condition worsened rapidly and he died five months after diagnosis despite four rounds of chemotherapy.
  • To our knowledge the association of blastomycosis and intravascular lymphoma has not been previously reported.
  • In immunocompromised patients, clinical findings can be alarming and the outcome can be rapidly fatal.
  • [MeSH-major] Blastomycosis / complications. Lymphoma, B-Cell / complications. Vascular Neoplasms / complications

  • Genetic Alliance. consumer health - Blastomycosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17784682.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Kiguchi K, Ishiwata I, Ishiwata C, Ishiwata E, Koshitaka Y, Iwata M, Okuda Y, Kobayashi Y, Wada Y, Ishizuka B, Ishikawa H: Establishment and characterization of human malignant lymphoma cell line derived from uterine cervix. Hum Cell; 2005 Mar;18(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of human malignant lymphoma cell line derived from uterine cervix.
  • Human uterine cervical malignant lymphoma (B-cell type) was cultured and the cell line (HIUML) was newly established.
  • The HIUML cells were round in shape and had a tendency to make floating clusters.
  • The cells had a smooth surface or protrusion on the margin of the cytoplasm, and proliferate in floatation.
  • The HIUML cells were not transplantable into nude mice but were successfully done in the cheek pouch of hamster with formation of malignant lymphoma.
  • Epstein-Barr virus was detected in the HIUML cells.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Animals. Antigens, CD / analysis. Cell Line, Tumor. Cell Proliferation. Cricetinae. Female. Herpesvirus 4, Human / isolation & purification. Humans. Karyotyping. Mesocricetus. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Time Factors


23. Ziakas PD, Karsaliakos P, Mylonakis E: Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica; 2009 Jul;94(7):998-1005
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.
  • This report evaluates the benefits from this strategy among lymphoma patients and develops a management approach for patients with prolonged immunosuppression.
  • A Medline search was conducted to retrieve published trials on HBsAg-positive lymphoma patients receiving prophylactic lamivudine during chemotherapy.
  • Rituximab maintenance in B-cell lymphomas was used as a paradigm of prolonged immunosuppression.
  • If 1,000 HBsAg-positive lymphoma patients receive prophylaxis, one will die from hepatitis B virus reactivation versus 25/1,000 if no prophylaxis is administered.
  • [MeSH-major] Hepatitis B / drug therapy. Hepatitis B / metabolism. Lamivudine / pharmacology. Lymphoma / drug therapy. Lymphoma / metabolism
  • [MeSH-minor] Antiviral Agents / pharmacology. Clinical Trials as Topic. Decision Support Techniques. Humans. Immunosuppression. Immunosuppressive Agents / pharmacology. Models, Biological. Reverse Transcriptase Inhibitors / pharmacology. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Nov 27;354(9193):1896-900 [10584742.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2925-30 [10576374.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):58-62 [11722410.001]
  • [Cites] Blood. 2002 Jan 15;99(2):724-5 [11799967.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):166-9 [11841412.001]
  • [Cites] Blood. 2002 Jul 15;100(2):391-6 [12091327.001]
  • [Cites] Transplantation. 2002 Jul 27;74(2):182-8 [12151729.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1296-303 [14607759.001]
  • [Cites] J Korean Med Sci. 2003 Dec;18(6):849-54 [14676442.001]
  • [Cites] J Hepatol. 2003;39 Suppl 1:S3-25 [14708673.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1742-9 [14724827.001]
  • [Cites] J Viral Hepat. 2004 Mar;11(2):97-107 [14996343.001]
  • [Cites] J Viral Hepat. 2004 Mar;11(2):141-7 [14996349.001]
  • [Cites] Hepatology. 2004 Mar;39(3):857-61 [14999707.001]
  • [Cites] Med Oncol. 2004;21(1):67-72 [15034216.001]
  • [Cites] Ann Hematol. 2004 May;83(5):270-5 [15060745.001]
  • [Cites] Clin Transplant. 2004 Jun;18(3):295-300 [15142051.001]
  • [Cites] Hematol J. 2004;5(4):325-8 [15297849.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Nov;19(11):1276-82 [15482535.001]
  • [Cites] Biometrics. 1985 Mar;41(1):55-68 [4005387.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Vaccine. 1995;13 Suppl 1:S16-7 [7571820.001]
  • [Cites] Vaccine. 1995;13 Suppl 1:S47-9 [7571830.001]
  • [Cites] N Engl J Med. 1997 Dec 11;337(24):1733-45 [9392700.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):61-8 [9654535.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1085-9 [16019563.001]
  • [Cites] J Infect Chemother. 2005 Aug;11(4):189-91 [16133710.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1320-5 [16470607.001]
  • [Cites] Leuk Res. 2006 Mar;30 Suppl 1:S11-5 [16750673.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Oct 1;24(7):1003-16 [16984494.001]
  • [Cites] Infection. 2006 Oct;34(5):282-4 [17033754.001]
  • [Cites] Hepatology. 2007 Feb;45(2):507-39 [17256718.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1307-12 [17613758.001]
  • [Cites] Curr Oncol Rep. 2007 Sep;9(5):378-83 [17706166.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1049-56 [17680650.001]
  • [Cites] Liver Int. 2008 Jan;28(1):28-38 [17976155.001]
  • [Cites] Hepatology. 2008 Mar;47(3):844-53 [18302293.001]
  • [Cites] Ann Intern Med. 2008 Apr 1;148(7):519-28 [18378948.001]
  • [Cites] Ann Hematol. 2008 Jun;87(6):481-5 [18299831.001]
  • [Cites] World J Gastroenterol. 2008 Dec 7;14(45):6902-10 [19058323.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Dec;6(12):1315-41; quiz 1286 [18845489.001]
  • [Cites] J Hepatol. 2009 Feb;50(2):227-42 [19054588.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):605-11 [19075267.001]
  • [Cites] Ann Hematol. 2009 Apr;88(4):375-7 [18726097.001]
  • [Cites] J Infect Dis. 1999 Dec;180(6):1757-62 [10558928.001]
  • [Cites] J Hepatol. 2000 Sep;33(3):469-75 [11020004.001]
  • (PMID = 19454492.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine
  • [Other-IDs] NLM/ PMC2704311
  •  go-up   go-down


24. Yamaguchi M, Kotani T, Nakamura Y, Ueda M: Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol; 2006 Jun;83(5):450-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
  • We report a case of refractory peripheral T-cell lymphoma (PTCL) successfully treated with a combination of fludarabine and cyclophosphamide (FLU/CY).
  • A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell, Peripheral / drug therapy. Neoplasms, Second Primary / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / drug effects. Etoposide / administration & dosage. Humans. Male. Methylprednisolone / administration & dosage. Prednisone / administration & dosage. Recurrence. Remission Induction. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Mar;104(3):612-3 [10086802.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):1010-5 [11359390.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):158-63 [2783376.001]
  • [Cites] Ann Hematol. 2003 Apr;82(4):247-50 [12707730.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1783-90 [2585020.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):356-63 [15024607.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2354-5 [8822958.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):790-4 [1373760.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Leuk Lymphoma. 1994 Jun;14(1-2):137-9 [7920220.001]
  • [Cites] Blood. 1988 Aug;72(2):436-41 [3261181.001]
  • [Cites] Blood. 1993 Jul 15;82(2):619-24 [8392401.001]
  • [Cites] Int J Hematol. 2004 Apr;79(3):260-5 [15168595.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):28-32 [1727921.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):987-94 [10694548.001]
  • [Cites] Hematol Oncol. 1987 Jul-Sep;5(3):175-87 [2888715.001]
  • [Cites] Acta Haematol. 2001;105(2):106-8 [11408715.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):120-3 [1713049.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):597-601 [10492085.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Leuk Res. 1991;15(9):837-46 [1656151.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):575-8 [8363989.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Pathol. 1992 Oct;168(2):229-36 [1334141.001]
  • [Cites] Blood. 2000 Jul 1;96(1):71-5 [10891432.001]
  • (PMID = 16787878.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


25. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, Saio M, Moriwaki H, Takami T: Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int; 2005 Jun;55(6):324-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
  • Although diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, it is both clinically and morphologically heterogenous.
  • The present study investigates the significance of survivin and a novel monoclonal antibody (MAb), T332, immunohistochemically for predicting the prognoses of DLBCL and its subtypes classified as germinal center B-cell-like type (GCB) and non-GCB type (NGCB) based on the expression profiles of CD10, bcl-6, and MUM1.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antigens, Neoplasm / biosynthesis. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Microtubule-Associated Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Animals. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Mice. Mice, Inbred BALB C. Middle Aged. Neoplasm Proteins. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943789.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Sugita S, Iijima T, Furuya S, Kano J, Yanaka A, Ohta K, Kojima H, Noguchi M: Gastric T-cell lymphoma with cytotoxic phenotype. Pathol Int; 2007 Feb;57(2):108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric T-cell lymphoma with cytotoxic phenotype.
  • Primary gastric lymphoma usually originates from B cells of mucosa-associated lymphoid tissue (MALT) infected with Helicobacter pylori.
  • When T-cell lymphomas develop in the stomach, they usually occur in association with infection by human T-lymphotropic virus type 1 and gastric involvement of adult T-cell leukemia.
  • Reported herein is a unique and informative case of gastric peripheral T-cell lymphoma with a cytotoxic phenotype that histologically mimicked, and had to be carefully distinguished from, MALT-type B-cell lymphoma.
  • The patient, a 73-year-old woman, underwent a gastric endoscopy examination, and the histological findings suggested MALT-type gastric lymphoma.
  • Analysis of the immunoglobulin heavy chain (IgH) gene and T cell receptor gamma (TCRgamma) gene revealed monoclonal rearrangement of the TCRgamma gene.
  • The tumor cells exhibited mild atypia and immunoreactivity with anti-CD3, anti-CD8, anti-T-cell intracellular antigen-1, antigranzyme B and antiperforin antibodies, but not with anti-CD20, anti-CD10, and anti-CD79a antibodies.
  • The case was finally diagnosed as gastric T-cell lymphoma with cytotoxic phenotype, and this was confirmed after surgical resection.
  • In cases such as this, small biopsy specimens from the stomach should be examined carefully for low grade B-cell-type malignant lymphoma (MALT lymphoma), because sometimes the proliferating B cells can hide the truly malignant T cells, and rearrangement analysis is useful for diagnosing T-cell malignancy.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Stomach Neoplasms / pathology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Aged. Base Sequence. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Molecular Sequence Data. Phenotype. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300676.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Number-of-references] 27
  •  go-up   go-down


27. Pavlović MD, Kamarachev J, Adamic M: Primary cutaneous epidermotropic marginal zone B-cell lymphoma: a role for antihistamines in maintaining lymphoma cell growth? J Eur Acad Dermatol Venereol; 2008 Aug;22(8):1012-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous epidermotropic marginal zone B-cell lymphoma: a role for antihistamines in maintaining lymphoma cell growth?
  • [MeSH-major] Histamine Antagonists / adverse effects. Lymphoma, B-Cell, Marginal Zone / chemically induced. Skin Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Cold and Cough Medicines.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503530.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histamine Antagonists
  •  go-up   go-down


28. Castillo JJ, Rizack T, Treaba D: Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma. Patholog Res Int; 2010;2011:563216
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma.
  • Patients with HIV/AIDS have a higher risk of developing aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL).
  • Lymphomas are rather heterogeneous in nature and in a few cases can switch their genetic or immunohistochemical phenotype, transform into other lymphomas or carry more than one malignant clone.
  • We postulate that the development of his refractory disease occurred in the context of an immunohistochemical switch or the surge of a clone refractory to therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151539.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2989698
  •  go-up   go-down


29. Sato T, Fujieda M, Tanaka E, Miyamura M, Chikamoto H, Hisano M, Akioka Y, Ishiura Y, Dohno S, Maeda A, Hattori M, Wakiguchi H: Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients. Pediatr Int; 2008 Aug;50(4):454-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epstein-Barr virus (EBV) infection can lead to life-threatening post-transplant lymphoproliferative disorder (PTLD).
  • METHODS: EBV-DNA load was investigated, using real-time polymerase chain reaction (PCR) and anti-EBV antibody titers, in peripheral blood mononuclear cells of 21 renal transplant patients (seven recipients who were EBV-seronegative, R[-]; 14 who were EBV-seropositive, R[+]) before grafting.
  • During follow up no patient in the R(+) group had any noticeable symptoms that could be related to EBV, but three recipients in the R(-) group developed EBV-related symptoms including adenoid hypertrophy, cervical lymphadenopathy, and PTLD (B cell lymphoma), in one patient each.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143966.001).
  • [ISSN] 1442-200X
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral
  •  go-up   go-down


30. Kan E, Levy I, Benharroch D: Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma. Ann Diagn Pathol; 2008 Aug;12(4):290-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma.
  • A case showing the typical clinical and pathological features of splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma is presented.
  • Since the series recorded by Dogan et al (Am J Surg Pathol 2003;27:903-911), there have been very few reports on this lymphoma variant.
  • Possible reasons for the scarcity of reports and for the confirmation of this lymphoma as a variant of T-cell-rich large B-cell lymphoma are discussed.
  • [MeSH-major] Histiocytes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Splenic Neoplasms / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620998.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Uzuka Y, Saitou Y, Saitou K, Suzuki S, Yamaguchi M: [Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1085-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma].
  • Excellent results were reported for dose-dense and dose-intense weekly combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide and additional ara-C) (CHOEA-7) and with rituximab (RCHOEA-7), for patients with CD 20-positive non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637545.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


32. Mudhar HS, Sethuraman C, Khan MD, Jan SU: Intracular, pan-uveal intravascular large B-cell lymphoma associated with choroidal infarction and choroidal tri-lineage extramedullary haemtopoiesis. Histopathology; 2007 Aug;51(2):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracular, pan-uveal intravascular large B-cell lymphoma associated with choroidal infarction and choroidal tri-lineage extramedullary haemtopoiesis.
  • [MeSH-major] Choroid Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593210.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


33. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, Chan WC, Delabie J, Braziel RM, Campo E, Gascoyne RD, Jaffe ES, Muller-Hermelink K, Ott G, Calaminici M, Norton AJ, Goff LK, Fitzgibbon J, Staudt LM, Andrew Lister T: Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol; 2007 Jan;136(2):286-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.
  • This study was undertaken to further elucidate the biological mechanisms underlying the frequent event of transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL).
  • Transformed follicular lymphoma was predominantly of the germinal centre B-like phenotype both at the mRNA and protein level.
  • Genes involved in cellular proliferation prevailed amongst those that were significantly increased upon transformation and T cell and follicular dendritic-associated genes predominated amongst those that decreased. t-FL is a germinal centre B (GCB)-like malignancy that evolves by two pathways, one that is similar in proliferation rate to the antecedent FL and the other that has a higher proliferation rate and is characterised by the presence of recognised oncogenic abnormalities.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):1017-24 [10702417.001]
  • [Cites] Blood. 2000 Jul 15;96(2):635-9 [10887128.001]
  • [Cites] Br J Haematol. 2000 Nov;111(2):618-25 [11122110.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2142-8 [11187904.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):727-35 [11157024.001]
  • [Cites] Br J Cancer. 2001 Feb;84(4):499-503 [11207045.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):202-8 [11328303.001]
  • [Cites] Immunity. 2001 Sep;15(3):375-85 [11567628.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7610-8 [11751859.001]
  • [Cites] Prostate. 2002 Apr 1;51(1):59-72 [11920959.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8886-91 [12077300.001]
  • [Cites] Lab Invest. 2003 Feb;83(2):271-85 [12594241.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3109-17 [12406872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7259-64 [12756297.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1443-8 [12738680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):915-23 [14562288.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Br J Haematol. 2004 Feb;124(3):325-8 [14717779.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):449-57 [15161443.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Cancer. 1979 Aug;44(2):645-51 [383259.001]
  • [Cites] Cancer Treat Rep. 1981 May-Jun;65(5-6):413-8 [7016324.001]
  • [Cites] Blood. 1982 Feb;59(2):258-64 [7034812.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):393-8 [6344979.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1527-32 [1875216.001]
  • [Cites] Science. 1992 May 8;256(5058):827-30 [1589764.001]
  • [Cites] Blood. 1992 Aug 1;80(3):758-67 [1638027.001]
  • [Cites] Blood. 1993 Oct 1;82(7):1994-2004 [8400252.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2289-95 [8400281.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:119-22 [9209654.001]
  • [Cites] Blood. 1998 Jan 1;91(1):331-9 [9414302.001]
  • [Cites] Oncogene. 1998 Jan 8;16(1):69-76 [9467944.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4677-85 [9616165.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4765-9 [10519380.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Blood. 2005 Jan 1;105(1):301-7 [15345589.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1459-65 [15902285.001]
  • (PMID = 17278262.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114778-01; United States / NCI NIH HHS / CA / U01 CA114778-01; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS39595; NLM/ PMC2532951
  •  go-up   go-down


34. Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M, Schmid U: IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol; 2005 Jul;206(3):320-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
  • Mantle cell lymphoma (MCL) is associated with a very unfavourable clinical course.
  • This is particularly true for mantle cell lymphoma of the blastoid subtype (MCL-b).
  • In order to define prognostic factors, we analysed the impact of immunoglobulin heavy chain variable (IgV H) gene somatic hypermutations on clinical outcome in a series of 21 cases of morphologically, phenotypically, and genotypically well-characterized MCL-b.
  • Thirteen of 21 cases of MCL-b revealed a homology rate of > or = 99% compared to IgV H germ-line sequences in the databases and were scored as non-mutated.
  • In MCL-b the mutation frequency was usually low and the mutation pattern was only rarely antigen-selected, in contrast to a control group of 11 cases with morphologically almost identical, but phenotypically and genotypically clearly distinguishable, diffuse large B cell lymphoma, derived, most likely, from germinal centre B cells.
  • However, mutated MCL-b tended to present more frequently at an earlier stage and without bone marrow involvement and to show lower rates of relapse and death, resulting in a more favourable clinical outcome.
  • [MeSH-major] Genes, Immunoglobulin / genetics. Lymphoma, Mantle-Cell / genetics

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 15887292.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


35. Oh DE, Kim YD: Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol; 2007 Dec;125(12):1668-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the clinical features, treatments, and outcomes of patients with ocular lymphoproliferative disease classified according to the World Health Organization classification and to determine prognostic factors of this disease in South Korea.
  • The major histopathologic subtypes were mucosa-associated lymphoid tissue (MALT) lymphoma in 96 patients (75.0%), lymphoid hyperplasia in 11 (8.6%), diffuse large B-cell lymphoma in 6 (4.7%), and mantle cell lymphoma in 4 (3.1%).
  • Twenty patients had tumor relapses (15.6%), and 9 died of lymphoma during follow-up (7.0%).
  • Regarding the analysis of prognostic factors, most patients with MALT lymphoma evidenced local disease, required local treatment, and exhibited a superior prognosis.
  • CONCLUSIONS: Lymphomas of the MALT type constitute most ocular adnexal lymphoproliferative diseases and occur more frequently in South Korea than in Western countries.
  • Patients with MALT lymphoma have favorable outcomes compared with patients with other types of lymphoma.
  • [MeSH-major] Conjunctival Neoplasms / epidemiology. Eyelid Neoplasms / epidemiology. Lymphoma, B-Cell, Marginal Zone / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Mantle-Cell / epidemiology. Orbital Neoplasms / epidemiology. Pseudolymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Korea / epidemiology. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071120.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Zhou WB, Wang R, Deng YN, Ji XB, Huang GX, Xu YZ: Study of Cbl-b dynamics in peripheral blood lymphocytes isolated from patients with multiple sclerosis. Neurosci Lett; 2008 Aug 8;440(3):336-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • E3 ubiquitin ligase Casitas B cell lymphoma-b (Cbl-b) has been recently highlighted as a negative regulator of T-cell activation and which dysfunction usually results in autoimmunity.
  • To present, however, the possible involvement of Cbl-b in multiple sclerosis (MS), an autoimmune demyelinating disease mediated by T-helper 1 (Th1) cells is still unclear.
  • In addition, it was shown that Cbl-b mRNA levels being inversely correlated with the frequency of MS clinical relapses (P<0.0001).
  • Altogether, the data show for the first time that Cbl-b dynamics in peripheral blood T-lymphocyte subset and which possible relationship with the clinical onsets during MS.

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565657.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
  •  go-up   go-down


37. Rodriguez FJ, Gamez JD, Vrana JA, Theis JD, Giannini C, Scheithauer BW, Parisi JE, Lucchinetti CF, Pendlebury WW, Bergen HR 3rd, Dogan A: Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest; 2008 Oct;88(10):1024-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied 13 cases of proteinaceous aggregates in clinical specimens of the nervous system.
  • LC-MS/MS demonstrated the presence of lambda, but not kappa, light chain as well as serum amyloid P in all amyloidomas. lambda-Light-chain immunostaining was noted in amyloid (n=5), although demonstrable monotypic lymphoplasmacytic cells were seen in only one case.
  • In three cases of PDNOS, a low-grade B-cell lymphoma consistent with marginal zone lymphoma was present in the brain specimen (n=2) or spleen (n=1).
  • In the second case, the crystals contained immunoglobulin G within CD138+ plasma cells.
  • Our results show that proteinaceous deposits in the nervous system contain immunoglobulin components and LC-MS/MS accurately identifies the content of these deposits in clinical biopsy specimens.
  • [MeSH-minor] Adult. Aged. Female. Histiocytosis / pathology. Humans. Immunoglobulin lambda-Chains / analysis. Lymphoma / pathology. Male. Middle Aged. Retrospective Studies. Serum Amyloid P-Component / analysis. Spectrometry, Mass, Electrospray Ionization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711355.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin lambda-Chains; 0 / Nerve Tissue Proteins; 0 / Serum Amyloid P-Component
  •  go-up   go-down


38. Jiang L, Admirand JH, Moran C, Ford RJ, Bueso-Ramos CE: Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature. Ann Diagn Pathol; 2006 Dec;10(6):357-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
  • We report a rare case of mediastinal follicular dendritic cell (FDC) sarcoma involving the bone marrow.
  • The patient, a 46-year-old woman, had a clinically aggressive tumor in the anterior mediastinum that was initially diagnosed as a diffuse B-cell lymphoma.
  • The diagnosis of FDC sarcoma was made based on histological examination and immunohistochemical findings, including strong positive staining of tumor cells for CD21, CD23, clusterin, and epidermal growth factor receptor (EGFR) and negative staining for CD20, CD30, CD45, CD1a, S-100, vimentin, and keratin cocktail.
  • Histological examination and immunohistochemical studies of a previous biopsy of the mediastinal mass confirmed the diagnosis of mediastinal FDC sarcoma.
  • The patient was treated with an appropriate chemotherapy regimen; 1 month later, follow-up bone marrow biopsy revealed no tumor cells.
  • This case also highlights the utility of EGFR as an immunohistochemical marker of dendritic cell tumors that could be used as a diagnostic tool and guide for choosing appropriate chemotherapy regimens.
  • [MeSH-major] Bone Marrow / pathology. Dendritic Cells, Follicular / pathology. Mediastinal Neoplasms / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126255.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


39. Lassmann S, Gerlach UV, Technau-Ihling K, Werner M, Fisch P: Application of BIOMED-2 primers in fixed and decalcified bone marrow biopsies: analysis of immunoglobulin H receptor rearrangements in B-cell non-Hodgkin's lymphomas. J Mol Diagn; 2005 Nov;7(5):582-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of BIOMED-2 primers in fixed and decalcified bone marrow biopsies: analysis of immunoglobulin H receptor rearrangements in B-cell non-Hodgkin's lymphomas.
  • The detection of clonality in lymphomas was recently improved by the BIOMED-2 approach, but analysis of fixed tissues is limited.
  • Here, we adapted the BIOMED-2 protocol for examining immunoglobulin H (IgH) receptor rearrangements in fixed, decalcified bone marrow biopsies (BMBs) for clonality analysis in B-cell non-Hodgkin's lymphomas (B-NHL).
  • Together, analysis of FRII and FRIII regions by the modified BIOMED-2 protocol increased the detection rate to 31 of 36 (86.1%), particularly for BMBs with histological evidence of follicular lymphoma (FRIII, 70%; FRII, 90%).
  • [MeSH-major] Bone Marrow / pathology. DNA Primers / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Genes, Immunoglobulin Heavy Chain / genetics. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Polymerase Chain Reaction / methods
  • [MeSH-minor] Biopsy. Cell Extracts. Clone Cells / pathology. DNA / genetics. DNA / isolation & purification. Decalcification Technique. Heteroduplex Analysis. Humans. Sensitivity and Specificity. Sequence Analysis, DNA. Tissue Fixation

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Jul;52(7):521-6 [10605406.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):46-51 [10963379.001]
  • [Cites] Ann Diagn Pathol. 2000 Apr;4(2):71-6 [10760319.001]
  • [Cites] Mol Pathol. 2000 Feb;53(1):19-23 [10884917.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):847-53 [10923923.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] J Clin Pathol. 2000 Nov;53(11):835-40 [11127265.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):92-6 [11272894.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):737-42 [11577117.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):81-9 [11986398.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):470-6 [12139734.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):129-32 [12560392.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):634-42 [12760281.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):79-87 [12766612.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Diagn Mol Pathol. 2004 Jun;13(2):116-25 [15167013.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1531-8 [15284865.001]
  • [Cites] JAMA. 1991 Jan 23-30;265(4):472-7 [1845912.001]
  • [Cites] J Histochem Cytochem. 1991 Mar;39(3):351-4 [1704393.001]
  • [Cites] Hum Pathol. 1994 Dec;25(12):1276-82 [8001921.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):850-5 [7801903.001]
  • [Cites] J Mol Med (Berl). 1995 May;73(5):235-41 [7670927.001]
  • [Cites] Pathology. 1997 Aug;29(3):309-12 [9271025.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1047-56 [9298881.001]
  • [Cites] Mol Pathol. 1999 Apr;52(2):104-10 [10474690.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):234-40 [15538114.001]
  • [Cites] J Pathol. 2000 Jan;190(1):55-60 [10640992.001]
  • (PMID = 16258156.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Extracts; 0 / DNA Primers; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1867555
  •  go-up   go-down


40. Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR: Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Mar;135(3):459-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
  • INTRODUCTION: Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL).
  • Consolidating involved-field irradiation was applied in patients with stage I/II, bulky disease, or localized residual lymphoma.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal / toxicity. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Remission Induction. Rituximab. Survival Analysis. Survivors. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):257-67 [8558207.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):619-27 [2205142.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1067-73 [11583187.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3722-7 [3458531.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):536-41 [16098067.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1864-71 [15143078.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2070-9 [9626206.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):277-81 [12562656.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):614-22 [16423847.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):93-101 [17313557.001]
  • [Cites] Tumori. 2007 Sep-Oct;93(5):409-16 [18038870.001]
  • [Cites] Ann Oncol. 1993 May;4(5):359-69 [8353070.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 18758815.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


41. Asproudis I, Gorezis S, Charonis GC, Tolis C, Tsanou E, Agnantis NJ: Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland--a case report. In Vivo; 2005 Nov-Dec;19(6):1105-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland--a case report.
  • MALT lymphoma of the ocular adnexa, an indolent B-cell lymphoma, rarely affects the lacrimal gland.
  • Clinical evaluation and imaging examination led to excision biopsy.
  • The mass histopathology, presenting organized lymphoid tissue, composed mainly of small B-cells, accompanied by immunophenotypic characteristics, was compatible with MALT lymphoma.
  • Treatment with monoclonal antibody against CD-20 achieved a successful long-term disease control (4 years).
  • The diagnostic approach is described and the pathological features and clinical signs of this rare entity are discussed, based on recent literature.
  • The indolent clinical course of this lymphoma, either remaining localized or disseminating to other mucosal sites, is a distinct characteristic affecting prognosis.
  • [MeSH-major] Lacrimal Apparatus / pathology. Lymphoma, B-Cell, Marginal Zone / pathology

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] In Vivo. 2006 Jan-Feb;20(1):193. Elena, Tsanou [corrected to Tsanou, Elena]
  • (PMID = 16277031.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


42. Matsumoto T, Kumagai J, Hasegawa M, Tamaki M, Aoyagi M, Ohno K, Mizusawa H, Kitagawa M, Eishi Y, Koike M: Significant increase in the expression of matrix metalloproteinase 7 in primary CNS lymphoma. Neuropathology; 2008 Jun;28(3):277-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant increase in the expression of matrix metalloproteinase 7 in primary CNS lymphoma.
  • The aim of this study is to compare the expression pattern of matrix metalloproteinases (MMP) in primary CNS lymphoma (PCNSL) with that of nodal lymphoma (NL).
  • Hypotheses have been proposed that this infiltration pattern indicates the infiltration of lympoma cells from outside the CNS.
  • Here we performed quantitative analysis of mRNA expression of MMP1, 2, 3, 7 and 9 in lymphoma cells from 10 cases of PCNSL, all of which were diagnosed as diffuse large B-cell lymphoma (DLBCL), and 14 cases of nodal DLBCL.
  • Immunohistochemistry was also performed for phenotyping of lymphoma cells and for examining the localization of MMPs.
  • Immunohistochemical phenotyping revealed that the frequency of non-germinal center type DLBCL was significantly higher in PCNSL than in NL.
  • [MeSH-major] Brain Neoplasms / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Matrix Metalloproteinase 7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179407.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


43. Liu KL, Chang CC, Huang KH, Tsang YM, Chen SJ: Imaging diagnosis of testicular lymphoma. Abdom Imaging; 2006 Sep-Oct;31(5):610-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis of testicular lymphoma.
  • Testicular lymphoma is a rare clinicopathologic entity that has rapid progression and poor prognosis.
  • Testicular lymphoma was considered, and biopsy confirmed a non-Hodgkin, large, B-cell lymphoma.
  • The finding may be a useful characteristic for timely diagnosis of testicular lymphoma, although the diagnosis should be suspected in an older patient who presents with a testicular neoplasm and increased lactic dehydrogenase levels but without increased alpha-fetoprotein and human chorionic gonadotropin levels.
  • [MeSH-major] Lymphoma, B-Cell / radiography. Testicular Neoplasms / pathology. Testicular Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Male. Middle Aged. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465583.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Byers RJ: Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood; 2007 May 1;109(9):3922-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.
  • Recent microarray gene expression profiling studies have identified gene signatures predictive of outcome, so-called "indicator" genes, for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
  • Six genes showed statistically significant higher expression in the neoplastic nodes compared with reactive nodes, namely PRKCB1, BCL-6, EAR2, ZFX, cyclin B, YY1.
  • The method is simple, sensitive, and robust, facilitating routine use and may be used as a platform for clinical measurement of prognostic gene signatures.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Lymphoma, B-Cell / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Neoplasm Proteins / biosynthesis. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Male. Predictive Value of Tests. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate


45. Cutlan JE, Rashid RM, Torres-Cabala C, Tyring SK, Thomas V: Epidermodysplasia verruciformis after cutaneous T-cell lymphoma: Periungual presentation. Dermatol Online J; 2010;16(8):12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermodysplasia verruciformis after cutaneous T-cell lymphoma: Periungual presentation.
  • Epidermodysplasia verruciformis (EV) has several clinical presentations and has been reported in various states of immune deregulation.
  • We report the unique presentation of this disease as a pigmented periungual macule in a patient with a previous history of immune deregulation related to cutaneous lymphoma.
  • A literature review did not reveal any previous reports of EV in patients with cutaneous T-cell lymphoma.
  • [MeSH-major] Epidermodysplasia Verruciformis / diagnosis. Lymphoma, T-Cell, Cutaneous / complications. Pigmentation Disorders / diagnosis. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Female. Humans. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Treatment Outcome


46. Callet-Bauchu E, Baseggio L, Felman P, Traverse-Glehen A, Berger F, Morel D, Gazzo S, Poncet C, Thieblemont C, Coiffier B, Magaud JP, Salles G: Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia; 2005 Oct;19(10):1818-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases.
  • The purpose of this study was to document the frequency and distribution of karyotypic changes present at diagnosis in 103 non-MALT marginal zone cell lymphoma (MZL) patients.
  • Trisomy 3/3q, 7q deletions, +18 and +12 were seen in different combinations in more than 30% of patients in comparison to 2% in lymphocytic lymphomas/chronic lymphocytic leukemias, 1% in mantle cell lymphomas and 7% in follicular lymphomas.
  • The marked propensity of these abnormalities to be recurrently associated with the same tumoral clone of individual karyotypes allowed the delineation of a cytogenetic profile that may help to distinguish non-MALT MZL among other mature B-cell neoplasms.
  • If +3/3q, +12/+12q, and 6q, 7q and 8p deletions were significantly associated with clinical prognostic factors previously reported to influence survival and time to progression, patients displaying these abnormalities did not experience a significantly shorter time to progression.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell, Marginal Zone / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Cohort Studies. Cytogenetic Analysis. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094418.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Sohn I, Kim J, Jung SH, Park C: Gradient lasso for Cox proportional hazards model. Bioinformatics; 2009 Jul 15;25(14):1775-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also results from diffuse large B-cell lymphoma datasets and Norway/Stanford breast cancer dataset indicate that our method is very competitive compared with popular existing methods by Park and Hastie and Goeman in its computational time, prediction and selectivity.
  • [MeSH-minor] Algorithms. Humans. Lymphoma, B-Cell / genetics. Proportional Hazards Models

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447787.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


48. Yin HF, Li T: [Helicobacter pylori genotypes of gastrointestinal B cell lymphoma]. Beijing Da Xue Xue Bao; 2006 Apr 18;38(2):189-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helicobacter pylori genotypes of gastrointestinal B cell lymphoma].
  • OBJECTIVE: To assess the expression of specific virulence-associated Helicobacter pylori (Hp) genotypes. (cag A, vac A, and ice A status) in primary gastrointestinal B cell lymphoma.
  • RESULTS: There were 14 cases of mucosa associated lymphoid tissue lymphoma (MALT-L) (8 in stomach, and 6 in intestine) and 35 cases of diffuse large B cell lymphoma (DLBCL) (21 in stomach, and 14 in intestine) in all.
  • CONCLUSION: High toxicity cag A+Hp strains seem to play a role in the pathogenesis of gastrointestinal B cell lymphoma, whereas vac A m2 may be more associated with MALT-L.
  • Clinical stage was not associated with virulence-associated Hp genotypes.
  • [MeSH-major] Helicobacter pylori / genetics. Lymphoma, B-Cell / microbiology. Stomach Neoplasms / microbiology
  • [MeSH-minor] Genotype. Humans. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / microbiology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617364.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


49. Nakamura S: [Overview of 2008 WHO Classification of Malignant Lymphoma]. Rinsho Byori; 2010 Nov;58(11):1105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overview of 2008 WHO Classification of Malignant Lymphoma].
  • Lymphoma classification is now evolving.
  • The 4th edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues was published in 2008, regarded as a revised and updated version of the 2001 3rd edition; an effort that involved 138 authors from 22 countries and two clinical advisory committees comprising 62 clinical specialists with expertise in lymphoid and myeloid disorders.
  • 1) a greater recognition of "early" lesions, i.e., an incipient neoplasm, e.g., in situ follicular lymphoma, has been incorporated;.
  • 2) age was highlighted as a defining feature of some neoplasms, e.g., EBV+ diffuse large B-cell lymphoma of the elderly, pediatric follicular lymphoma, and EBV+ T-cell lymphoproliferative diseases of childhood;.
  • 3) anatomical sites were noted as having an important impact on disease definitions; and 4) newly recognized borderline categories were listed on the basis of their biological overlap between diffuse large B-cell lymphoma and Burkitt lymphoma or classical Hodgkin lymphoma.
  • [MeSH-major] Lymphoma / classification. World Health Organization
  • [MeSH-minor] Aged. Aged, 80 and over. Burkitt Lymphoma. Child. Herpesvirus 4, Human. Hodgkin Disease. Humans. Lymphoma, Follicular. Lymphoma, Large B-Cell, Diffuse. Lymphoproliferative Disorders

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21229709.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


50. Takahara Y, Kawashima H, Han YS, Sugimura N, Nakatani T, Tanaka K, Hino M: [Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder]. Hinyokika Kiyo; 2005 Jan;51(1):45-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder].
  • Cystoscopy revealed a wide-based submucosal mass, and biopsied specimens of the mass showed a B-cell lymphoma of the MALT type.
  • The findings were consistent with extranodal marginal zone B-cell lymphoma of the MALT type.
  • No evidence of lymphoma was found on the CT of the pelvis, chest X-ray and Gallium scintigraphy.
  • The patient had stages I(AE) lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy. Urinary Bladder Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732342.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Westin JR, Fayad LE: Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep; 2009 Oct;4(4):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in Western countries and represents a heterogeneous group of diseases.
  • Historically, the disease has been stratified based solely on clinical prognostic factors, such as those that make up the International Prognostic Index (IPI).
  • In the past decade, many advances have been made in understanding the biology of DLBCL, including clinical aspects, gene expression profiling, and microRNA.
  • These evaluations have revealed several distinct subtypes with differing responses to therapy and different long-term outcomes, but the standard initial therapy for DLBCL continues to use regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regardless of the disease subtype.
  • Despite improvements in the diagnosis and treatment of this condition, nearly one third of patients die of their disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / metabolism

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Ann Oncol. 1994 Nov;5(9):847-9 [7848887.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6681-90 [19278952.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] Ann Oncol. 1992 Nov;3(9):711-7 [1450060.001]
  • [Cites] Blood. 2007 Jan 15;109 (2):843-4; discussion 844-5 [17210865.001]
  • [Cites] Blood. 1995 May 15;85(10):2885-99 [7537983.001]
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Mod Pathol. 1990 May;3(3):361-7 [2194216.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1682-8 [15117990.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Leuk Lymphoma. 2009 Aug;50(8):1257-60 [19544140.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4251-8 [14976040.001]
  • [Cites] Leuk Lymphoma. 1993 Aug;10(6):433-41 [8401180.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1118-26 [19448608.001]
  • [Cites] Cancer. 1976 Oct;38(4):1484-93 [791473.001]
  • [Cites] J Nucl Med. 2009 Apr;50(4):527-33 [19289424.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):747-52 [14514777.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):501-10 [14742256.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Cancer Treat Rep. 1977 Sep;61(6):1023-7 [902260.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):35-40 [9440720.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Leuk Lymphoma. 2007 Nov;48(11):2213-20 [17926187.001]
  • [Cites] Br J Haematol. 2008 May;141(5):676-80 [18422776.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):729-33 [11895902.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):995-1007 [16418498.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):597-606 [15916681.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3712-8 [11090051.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1906-14 [19273713.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4207-13 [16449523.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4587-94 [18662967.001]
  • [Cites] Blood. 2001 Aug 15;98(4):945-51 [11493437.001]
  • (PMID = 20425411.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 58
  •  go-up   go-down


52. Turner SD, Merz H, Yeung D, Alexander DR: CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res; 2006 Sep-Oct;26(5A):3275-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.
  • BACKGROUND: Nucleophosmin-anaplastic lymphoma kinase expression is associated with a lymphoid malignancy, anaplastic large cell lymphoma, and is characterized by a t(2;5) chromosomal translocation.
  • MATERIALS AND METHODS: We describe a novel transgenic mouse line in which NPM-ALK expression is targeted to the T-cell lineage using the CD2 promoter.
  • RESULTS: Surprisingly, the mice develop B cell lymphomas in the majority of cases.
  • [MeSH-major] Antigens, CD2 / genetics. Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, T-Cell / genetics. Promoter Regions, Genetic. Protein-Tyrosine Kinases / physiology
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Lineage. Female. Genotype. Humans. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Oncogene Proteins, Fusion / physiology. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094440.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD2; 0 / Oncogene Proteins, Fusion; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


53. Hatake K, Yokoyama M, Terui Y: [Recent progress in rituximab therapy and its resistance--how do we overcome?]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1177-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the introduction of rituximab to chemotherapy in lymphoma, CHOP changed to R-CHOP in elderly, intermediate risk DLBCL (diffuse large B-cell lymphoma) patients.
  • Although the treatment is not yet standard, due to insufficient evidence, in clinical practice it is an R-containing regimen, for example, in mantle cell lymphoma, such as HyperCVAD/MA to R-HyperCVAD/MA.
  • If the lymphoma is bulky,the overexpression of CD 55 (complement regulatory molecule) leads to resistance to rituximab.
  • When the patients evidenced the loss of CD 20 antigen in refractory/relapsed lymphoma after R-containing therapy, some patients showed the presence of CD 20 point mutation.
  • In Japan, we must consider the higher speed of infusion rituximab and we must prepare standard therapy for lymphoma because of recruiting phase I/II clinical trials after use of rituximab for easy entry.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / genetics. Antigens, CD55 / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Histone Deacetylase Inhibitors. Humans. Point Mutation. Prednisone / administration & dosage. Pyrazines / therapeutic use. Rituximab. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687198.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD55; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Histone Deacetylase Inhibitors; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 20
  •  go-up   go-down


54. Zhang W, Li L, Li X, Jiang W, Huo J, Wang Y, Lin M, Rao S: Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering. BMC Genomics; 2007;8:332
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering.
  • BACKGROUND: It becomes increasingly clear that our current taxonomy of clinical phenotypes is mixed with molecular heterogeneity.
  • Of vital importance for refined clinical practice and improved intervention strategies is to define the hidden molecular distinct diseases using modern large-scale genomic approaches.
  • The aim of this study was thus to develop a bioinformatics approach to seek the transcriptional features leading to the hidden subtyping of a complex clinical phenotype.
  • The basic strategy of the proposed method was to iteratively partition in two ways sample and feature space with super-paramagnetic clustering technique and to seek for hard and robust gene clusters that lead to a natural partition of disease samples and that have the highest functionally conceptual consensus evaluated with Gene Ontology.
  • RESULTS: We applied the proposed method to two publicly available microarray datasets of diffuse large B-cell lymphoma (DLBCL), a notoriously heterogeneous phenotype.
  • CONCLUSION: Our results showed that the proposed algorithm is a promising computational strategy for peeling off the hidden genetic heterogeneity based on transcriptionally profiling disease samples, which may lead to an improved diagnosis and treatment of cancers.
  • [MeSH-major] Genetic Heterogeneity. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] J Immunol. 1994 Jul 15;153(2):682-90 [8021504.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12079-84 [11035779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):413-22 [11934740.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Genome Res. 2002 Oct;12(10):1574-81 [12368250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1128-33 [12538875.001]
  • [Cites] Pac Symp Biocomput. 2003;:601-12 [12603061.001]
  • [Cites] Methods Mol Biol. 2003;224:159-82 [12710673.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1079-89 [12801868.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1153-4 [12801877.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):125-38 [12853585.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1443-8 [12738680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Bioinformatics. 2004 Apr 12;20(6):979-81 [14764576.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6745-50 [10359783.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] BMC Immunol. 2004 Sep 15;5:20 [15369600.001]
  • [Cites] Genomics. 2005 Jan;85(1):16-23 [15607418.001]
  • [Cites] Bioinformatics. 2005 Feb 15;21(4):451-5 [15608048.001]
  • [Cites] BMC Bioinformatics. 2005;6:58 [15774002.001]
  • [Cites] BMC Bioinformatics. 2005;6:82 [15804359.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S31-7 [15920528.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1770-7 [15886317.001]
  • [Cites] J Pathol. 2006 Aug;209(4):454-63 [16739114.001]
  • [Cites] Mol Med. 2006 Jan-Mar;12(1-3):25-33 [16838067.001]
  • [Cites] BMC Bioinformatics. 2006;7:397 [16945146.001]
  • [Cites] Bioinformatics. 2006 Dec 1;22(23):2883-9 [16809389.001]
  • [Cites] Community Dent Oral Epidemiol. 2004 Jun;32(3):201-9 [15151690.001]
  • [Cites] Nature. 1999 Dec 2;402(6761 Suppl):C47-52 [10591225.001]
  • (PMID = 17888167.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2082044
  •  go-up   go-down


55. Wang DY, Zhang HQ, Li X: [Apoptosis induced by the C21 sterols in Baishouwu and its mechanism of action in hepatoma]. Yao Xue Xue Bao; 2007 Apr;42(4):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is to investigate the effect of the C21 sterols on inducing apoptosis of hepatocellular cancer cells and its potential mechanism.
  • The tumor cells were harvested and cell viability or apoptosis was analyzed by acridine orange and ethidium bromide (AO/EB) stain.
  • B-cell lymphoma/leukemia-2 gene (bcl-2) in tumor cells was inspected by immunohistochemistry.
  • Apoptosis induced by the C21 sterols was observed, low growth density and some apoptotic cells were observed in tumor under the electron microscope.
  • The expression of bcl-2 gene on tumor cells decreased in the C21 sterols groups, but the percentage of positive area is higher in 40 mg x kg(-1) group than that in 20 mg x kg(-1) group, which differed from apoptosis results.
  • Inhibiting the excessive expression of bcl-2 gene to promote apoptosis may be one of anti-tumor mechanisms for the C21 sterols in Baishouwu.
  • [MeSH-major] Apoptosis / drug effects. Cynanchum. Liver Neoplasms, Experimental / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Sterols / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / isolation & purification. Antineoplastic Agents, Phytogenic / pharmacology. Female. Gene Expression Regulation, Neoplastic. Genes, bcl-2. Male. Mice. Mice, Inbred ICR. Neoplasm Transplantation. Plants, Medicinal / chemistry. Random Allocation. Tumor Burden / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633201.001).
  • [ISSN] 0513-4870
  • [Journal-full-title] Yao xue xue bao = Acta pharmaceutica Sinica
  • [ISO-abbreviation] Yao Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sterols
  •  go-up   go-down


56. Kim HN, Yu L, Kim NY, Lee IK, Kim YK, Yang DH, Lee JJ, Shin MH, Park KS, Choi JS, Kim HJ: Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol; 2010 Oct;85(10):822-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma.
  • Few studies have investigated its role in the susceptibility to non-Hodgkin lymphoma (NHL) [5,6].
  • The TP53 72CC genotype was associated with increased risk of NHL (P 5 0.04) and diffuse large B-cell lymphoma (P 5 0.04).
  • [MeSH-major] Genes, p53. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Codon / genetics. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Republic of Korea / epidemiology. Risk. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734458.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


57. Contreras-Ibáñez JA, Díaz-Gómez L, Muriel-Cueto P: [Renal synchronous carcinoma of clear cells with non-hodgkin lymphoma of phenotype b of type MALT]. Actas Urol Esp; 2010 Oct;34(9):818-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal synchronous carcinoma of clear cells with non-hodgkin lymphoma of phenotype b of type MALT].
  • [Transliterated title] Carcinoma renal de células claras sincrónico con linfoma no hodgkiniano de fenotipo B de tipo MALT.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms. Lymphoma, B-Cell, Marginal Zone. Neoplasms, Multiple Primary


58. Latta S, Myint ZW, Jallad B, Hamdi T, Alhosaini MN, Kumar DV, Kheir F: Primary central nervous system T-cell lymphoma in aids patients: case report and literature review. Curr Oncol; 2010 Oct;17(5):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system T-cell lymphoma in aids patients: case report and literature review.
  • According to the published data, most primary central nervous system lymphomas (PCNSLs) are B-cell lymphomas; primary T-cell lymphomas are rare.
  • In a search of the MEDLINE database, we found only 6 cases of primary T-cell PCNSL.
  • A biopsy showed T-cell lymphoma, and the patient was subsequently treated with whole-brain radiation, to marked clinical response.
  • Reported cases from the literature of primary T-cell PCNSL in AIDS patients are summarized in this review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975881.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2949374
  • [Keywords] NOTNLM ; Primary cns lymphoma / T cells / aids / non-Hodgkin lymphoma
  •  go-up   go-down


59. Haydeé Cottliar AS, Noriega MF, Narbaitz M, Rodríguez A, Slavutsky IR: Association between telomere length and BCL2 gene rearrangements in low- and high-grade non-Hodgkin lymphomas. Cancer Genet Cytogenet; 2006 Nov;171(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between telomere length and BCL2 gene rearrangements in low- and high-grade non-Hodgkin lymphomas.
  • Telomere length based on terminal restriction fragment (TRF) assay was evaluated in cells of bone marrow, lymph node, or both from 53 non-Hodgkin lymphoma (NHL) patients: 44 with follicular lymphoma (FL) and 9 with secondary diffuse large B-cell lymphoma (S-DLBCL) to FL.
  • Peripheral blood cells from 12 healthy donors were studied as controls.
  • Even though the number of S-DLBCL cases was small, they showed the shortest telomere length, suggesting that this parameter reflects another genetic alteration involved in the progression from FL to a higher-grade lymphoma.
  • [MeSH-major] Gene Rearrangement. Lymphoma, Non-Hodgkin / pathology. Proto-Oncogene Proteins c-bcl-2 / genetics. Telomere / genetics
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Deoxyribonucleases, Type II Site-Specific / metabolism. Electrophoresis, Agar Gel. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074584.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.1.21.4 / Deoxyribonucleases, Type II Site-Specific; EC 3.1.21.4 / GANTC-specific type II deoxyribonucleases; EC 3.1.21.4 / GTAC-specific type II deoxyribonucleases
  •  go-up   go-down


60. Ding H, Prodinger WM, Kopecek J: Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates. Bioconjug Chem; 2006 Mar-Apr;17(2):514-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using phage display under stringent screening conditions, we selected five distinct peptides that specifically recognized the CD21 receptor, a cell surface marker of malignant B cell lymphoma.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYPROPYL METHACRYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536485.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA51578; United States / NCI NIH HHS / CA / CA88047
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Methacrylates; 0 / Peptide Library; 0 / Peptides; 0 / Receptors, Complement 3d; 27813-02-1 / hydroxypropyl methacrylate
  •  go-up   go-down


61. Bhattacharyya S, Liu H, Zhang Z, Jam M, Dudeja PK, Michel G, Linhardt RJ, Tobacman JK: Carrageenan-induced innate immune response is modified by enzymes that hydrolyze distinct galactosidic bonds. J Nutr Biochem; 2010 Oct;21(10):906-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mechanisms of CGN-induced nuclear factor κB and interleukin-8 (IL-8) stimulation include an immune-mediated pathway involving toll-like receptor 4 (TLR4) and B-cell lymphoma/leukemia 10 (BCL10) and a reactive oxygen species (ROS)-mediated pathway.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Shock. 2005 Feb;23(2):186-93 [15665736.001]
  • [Cites] Nat Genet. 1999 May;22(1):63-8 [10319863.001]
  • [Cites] Immunol Cell Biol. 2005 Dec;83(6):674-86 [16266320.001]
  • [Cites] FEMS Microbiol Rev. 2006 May;30(3):382-403 [16594963.001]
  • [Cites] Appl Microbiol Biotechnol. 2006 Jun;71(1):23-33 [16550377.001]
  • [Cites] Carbohydr Res. 2006 Aug 14;341(11):1859-69 [16716278.001]
  • [Cites] Transplantation. 2007 Jan 27;83(2):193-201 [17264816.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G829-38 [17095757.001]
  • [Cites] Biochem J. 2007 May 15;404(1):105-14 [17269933.001]
  • [Cites] J Immunoassay Immunochem. 2007;28(3):173-88 [17613665.001]
  • [Cites] Cell. 2007 Sep 7;130(5):906-17 [17803912.001]
  • [Cites] Dig Dis Sci. 2007 Oct;52(10):2766-74 [17429723.001]
  • [Cites] Biochemistry. 2007 Oct 30;46(43):12482-90 [17924664.001]
  • [Cites] J Nutr. 2008 Mar;138(3):469-75 [18287351.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1109-17 [18337601.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10550-8 [18252714.001]
  • [Cites] Biochim Biophys Acta. 2008 Jul-Aug;1780(7-8):973-82 [18452717.001]
  • [Cites] J Clin Invest. 2000 Feb;105(3):301-10 [10675356.001]
  • [Cites] Med Hypotheses. 2001 May;56(5):589-98 [11388773.001]
  • [Cites] Structure. 2001 Jun;9(6):513-25 [11435116.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):40202-9 [11493601.001]
  • [Cites] Environ Health Perspect. 2001 Oct;109(10):983-94 [11675262.001]
  • [Cites] Carbohydr Res. 2002 Mar 1;337(5):433-40 [11861017.001]
  • [Cites] Nature. 2004 Jan 8;427(6970):167-71 [14695475.001]
  • [Cites] Front Biosci. 1997 Apr 1;2:e1-11 [9159186.001]
  • [Cites] Adv Carbohydr Chem Biochem. 1969;24:267-332 [4913938.001]
  • [Cites] Lancet. 1970 Dec 26;2(7687):1361 [4098931.001]
  • [Cites] Cancer Lett. 1981 Dec;14(3):267-72 [7332904.001]
  • [Cites] Prog Clin Biol Res. 1985;186:237-45 [4034603.001]
  • [Cites] Ann Clin Lab Sci. 1990 Nov-Dec;20(6):420-6 [2073092.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1996 Jun;32(6):315-7 [8842743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14677-82 [9405672.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Vet Microbiol. 2005 Apr 10;106(3-4):241-8 [15778030.001]
  • (PMID = 19864123.001).
  • [ISSN] 1873-4847
  • [Journal-full-title] The Journal of nutritional biochemistry
  • [ISO-abbreviation] J. Nutr. Biochem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK054016; United States / NIGMS NIH HHS / GM / R01 GM038060; United States / NIGMS NIH HHS / GM / GM38060
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Galactosides; 0 / Reactive Oxygen Species; 9000-07-1 / Carrageenan; EC 3.2.1.- / Galactosidases
  • [Other-IDs] NLM/ NIHMS139915; NLM/ PMC2888704
  •  go-up   go-down


62. Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE: Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood; 2005 May 1;105(9):3722-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of mantle-cell lymphoma by protein microarray.
  • Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable.
  • Protein overexpression was defined as a higher than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared with normal B-cell control.
  • These included cell cycle regulators (regulator of chromosome condensation 1 [RCC1], murine double minute 2 [MDM2]), a kinase (citron Rho-interacting kinase [CRIK]), chaperone proteins (heat shock 90-kDa protein [Hsp90], Hsp10), and phosphatase regulators (A-kinase anchor protein 1 [AKAP149], protein phosphatase 5 [PP5], and inhibitor 2).

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1993 Jan;120(2):313-23 [8421051.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3337-45 [1630449.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2124-30 [8187765.001]
  • [Cites] Biochem J. 1995 Oct 1;311 ( Pt 1):17-29 [7575450.001]
  • [Cites] Leuk Lymphoma. 1996 May;21(5-6):391-7, color plates XVI following 5 [9172803.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1922-30 [9586911.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):329-36 [9640217.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29706-11 [9792683.001]
  • [Cites] Adv Anat Pathol. 1998 Nov;5(6):376-98 [10095879.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:127-30 [10707794.001]
  • [Cites] Am J Hematol. 2000 Jul;64(3):190-6 [10861815.001]
  • [Cites] J Immunother. 2000 Sep-Oct;23(5):519-27 [11001545.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3922-31 [11090079.001]
  • [Cites] Am J Hematol. 2001 Jun;67(2):84-92 [11343379.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2171-7 [11360201.001]
  • [Cites] Pathol Int. 2001 Oct;51(10):747-61 [11881727.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):304-13 [12096112.001]
  • [Cites] Histopathology. 2002 Oct;41(4):322-30 [12383214.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1141-50 [12414343.001]
  • [Cites] Curr Opin Chem Biol. 2003 Feb;7(1):55-63 [12547427.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1442-50 [12628936.001]
  • [Cites] Electrophoresis. 2003 Jul;24(14):2376-85 [12874873.001]
  • [Cites] Mass Spectrom Rev. 2003 Jul-Aug;22(4):272-84 [12884390.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7777-84 [14633703.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8226-32 [14678979.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):274-81 [14688335.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):13-9 [14999150.001]
  • [Cites] J Leukoc Biol. 2004 May;75(5):772-6 [14982944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8625-30 [15173575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6807-20 [15501957.001]
  • [Cites] Leukemia. 1991 Sep;5(9):733-7 [1943225.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):80-2 [1944575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10830-4 [1961752.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Jun;15(3):179-86 [8347257.001]
  • (PMID = 15650054.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA15083-29C1; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1895014
  •  go-up   go-down


63. Yasuda H, Ando J, Matsumoto T, Ogura K, Ozaki Y, Aritaka N, Aoki Y, Sugita M, Nomura T, Sekii H, Yamaguchi N, Iguchi S, Yamamoto T, Komatsu N, Hirano T: Intravascular large B cell lymphoma with hepatic portal vein, splenic vein and mesenteric vein tumour embolism. Histopathology; 2010 Oct;57(4):648-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B cell lymphoma with hepatic portal vein, splenic vein and mesenteric vein tumour embolism.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Mesenteric Veins / pathology. Neoplastic Cells, Circulating / pathology. Portal Vein / pathology. Splenic Vein / pathology

  • Genetic Alliance. consumer health - Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20955393.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


64. Pangalis GA, Kyrtsonis MC, Kontopidou FN, Siakantaris MP, Dimopoulou MN, Vassilakopoulos TP, Tzenou T, Kokoris S, Dimitriadou E, Kalpadakis C, Tsalimalma K, Tsaftaridis P, Panayiotidis P, Angelopoulou MK: Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders. Clin Lymphoma; 2005 Mar;5(4):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
  • Differential diagnosis from other B-cell disorders (BCDs) is usually easy based on clinical, morphologic, histopathologic, immunophenotypic, and genetic features.
  • Eighty-four patients were diagnosed with WM, 5 with IgM-monoclonal gammopathy of undetermined significance (MGUS), and 41 with other BCDs (9 with B-cell chronic lymphocytic leukemia, 5 with small lymphocytic lymphoma, 14 with marginal zone lymphoma, 5 with mantle-cell lymphoma, 2 with follicular lymphoma, 2 with diffuse large B-cell lymphoma, 2 with cryoglobulinemia, and 2 with low-grade lymphoma not otherwise specified).
  • In 10% of non-WM BCDs, monoclonal IgM was found only when more sensitive immunofixation methods were used.
  • Forty-four percent of patients with BCDs (splenic marginal zone lymphoma or small lymphocytic lymphoma) had diagnoses that corresponded to that of WM.
  • Careful diagnosis requires the concomitant evaluation of all parameters of BCDs together.
  • Marginal zone lymphoma is the most frequently overlapping entity.
  • Special attention should be given to mantle cell lymphoma in its atypical forms.
  • Research in this field should continue to further clarify the disease entities that overlap with WM.
  • [MeSH-major] Immunoglobulin M / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma / diagnosis. Waldenstrom Macroglobulinemia / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / immunology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794855.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


65. Lin PW, Huang YJ, John JA, Chang YN, Yuan CH, Chen WY, Yeh CH, Shen ST, Lin FP, Tsui WH, Chang CY: Iridovirus Bcl-2 protein inhibits apoptosis in the early stage of viral infection. Apoptosis; 2008 Jan;13(1):165-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iridovirus Bcl-2 protein inhibits apoptosis in the early stage of viral infection.
  • The grouper iridovirus (GIV) belongs to the family Iridoviridae, whose genome contains an antiapoptotic B-cell lymphoma (Bcl)-2-like gene.
  • UV-irradiated grouper kidney (GK) cells underwent apoptosis.
  • However, a DNA fragmentation assay of UV-exposed GK cells after GIV infection revealed an inhibition of apoptosis.
  • The DNA ladder assay for GIV-infected GK cells after UV irradiation confirmed that apoptosis inhibition was an early process which occurred as early as 5 min post-infection.
  • A GIV-Bcl sequence comparison showed distant sequence similarities to that of human and four viruses; however, all possessed the putative Bcl-2 homology (BH) domains of BH1, BH2, BH3, and BH4, as well as a transmembrane domain.
  • Northern blot hybridization showed that GIV-Bcl transcription began at 2 h post-infection, and the mRNA level significantly increased in the presence of cycloheximide or aphidicolin, indicating that this GIV-Bcl is an immediate-early gene.
  • This was consistent with the Western blot results, which also revealed that the virion carries the Bcl protein.
  • We observed the localization of GIV-Bcl on the mitochondrial membrane and other defined intracellular areas.
  • By immunostaining, it was proven that GIV-Bcl-expressing cells effectively inhibited apoptosis.
  • Taken together, these results demonstrate that GIV inhibits the promotion of apoptosis by GK cells, which is mediated by the immediate early expressed viral Bcl gene.
  • [MeSH-major] Apoptosis. Iridovirus / physiology. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Aphidicolin / pharmacology. Base Sequence. Cell Line. Cycloheximide / pharmacology. DNA Fragmentation. Enzyme Inhibitors / pharmacology. Genes, bcl-2. Molecular Sequence Data. Perciformes. Protein Conformation. Protein Structure, Tertiary. Protein Synthesis Inhibitors / pharmacology. Ultraviolet Rays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17955372.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Protein Synthesis Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 38966-21-1 / Aphidicolin; 98600C0908 / Cycloheximide
  •  go-up   go-down


66. Torlakovic EE, Bilalovic N, Golouh R, Zidar A, Angel S: Prognostic significance of PU.1 in follicular lymphoma. J Pathol; 2006 Jul;209(3):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of PU.1 in follicular lymphoma.
  • Very few prognostic factors are known in follicular lymphoma (FL), a common malignancy of germinal centre (GC) B-cells.
  • The Follicular Lymphoma International Prognostic Index (FLIPI) thus far appears to be the most important predictor of clinical outcome.
  • Results for PFS were independent of the International Prognostic Index or the Italian Lymphoma Intergroup prognostic index for CD75 and PU.1, but only PU.1 expression was independent of FLIPI for PFS and OS.
  • Oct-2 was weakly expressed overall, but more strongly in higher grades of FL; it had a trend for negative linear association with PU.1 and strong positive linear association with CD27, which possibly reflects its role in terminal B-cell differentiation.
  • We show that the level of GC differentiation, as determined by the levels of PU.1, CD75, CD20, Bcl-6, and CD10 expression, has an association with outcome in patients with FL.
  • While this is determined qualitatively in most studies of diffuse large B-cell lymphoma, in FL there is a quantitative positive association between a high level of expression of GC antigens and longer OS and PFS even when data are stratified by the FLIPI score.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lymphoma, Follicular / diagnosis. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD20 / metabolism. Antigens, CD27 / metabolism. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Proteins / metabolism. Octamer Transcription Factor-2 / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Sialyltransferases. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Follicular lymphoma 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16639693.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD27; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-2; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; EC 2.4.99.- / Sialyltransferases; EC 2.4.99.1 / ST6GAL1 protein, human
  •  go-up   go-down


67. Andratschke M, Stelter K, Ihrler S, Hagedorn H: Subglottic tracheal stenosis as primary manifestation of a marginal zone B-cell lymphoma of the larynx. In Vivo; 2005 May-Jun;19(3):547-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subglottic tracheal stenosis as primary manifestation of a marginal zone B-cell lymphoma of the larynx.
  • BACKGROUND: More than 90% of laryngeal tumors are squamous cell carcinomas.
  • Primary hematopoetic neoplasms of the larynx are rare, being mainly extramedullary plasmocytoma and non-Hodgkin's lymphoma (NHL).
  • The biopsy revealed the diagnosis of a MALT-type lymphoma (marginal zone B-cell lymphoma).
  • CONCLUSION: This is the first report of a subglottic MALT-type lymphoma causing a tracheal stenosis.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Tracheal Stenosis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875774.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


68. Yang DT, Dunphy CH, Tripp SR, Lagoo AS, Perkins SL: Nodular lymphocyte predominant Hodgkin lymphoma at atypical locations may be associated with increased numbers of large cells and a diffuse histologic component. Am J Hematol; 2008 Mar;83(3):218-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma at atypical locations may be associated with increased numbers of large cells and a diffuse histologic component.
  • Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) typically affects predictable lymph node groups with excellent treatment outcomes, but cases with a diffuse histologic pattern are associated with recurrence and rarely, cases will transform to diffuse large B-cell lymphoma.
  • Although increased numbers of large cells has not been associated with poor prognosis, transformation is thought to histologically progress through a stage distinguished by increasing numbers of large atypical B-cells.
  • From 55 cases of NLPHL, we describe a possible subset of NLPHL occurring in older individuals at atypical sites, associated with increased numbers of large cells, a diffuse histologic component, and expression of Bcl-2.
  • [MeSH-major] Hodgkin Disease / classification. Hodgkin Disease / pathology. Lymph Nodes / pathology. Lymphocytes / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17918256.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Sekikawa T, Takahara S, Suzuki H, Takeda N, Yamada H, Horiguchi-Yamada J: Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas. Eur J Haematol; 2007 Mar;78(3):264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas.
  • Richter's syndrome occurs in 5-10% of patients with chronic lymphocytic leukemia, either by transformation of the primary neoplastic lymphocyte, or as a distinct B-cell neoplasm.
  • We report a Japanese patient with lymphoplasmacytic lymphoma in whom a diffuse large B-cell lymphoma developed after treatment with rituximab.
  • Molecular examination on immunoglobulin VH genes revealed that the lymphomas had arisen in two separate clones.
  • We reviewed clinical case reports in literature, and found 30-40% of cases with Richter's syndrome and composite lymphoma had a second B-cell lymphoma of a different origin.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253969.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger
  • [Number-of-references] 32
  •  go-up   go-down


70. Lu J, Verma SC, Murakami M, Cai Q, Kumar P, Xiao B, Robertson ES: Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation. J Virol; 2009 Jul;83(14):7129-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation.
  • Survivin is a master regulator of cell proliferation and cell viability and is highly expressed in most human tumors.
  • In this study, we show that latency-associated nuclear antigen (LANA), a multifunctional protein of Kaposi's sarcoma-associated herpesvirus (KSHV) that is found in Kaposi's sarcoma tumors, upregulates survivin expression and increases the proliferation of KSHV-infected B cells.
  • Analysis of pathway-specific gene arrays showed that survivin expression was highly upregulated in BJAB cells expressing LANA.
  • The mRNA levels of survivin were also upregulated in HEK 293 and BJAB cells expressing LANA.
  • Similarly, protein levels of survivin were significantly higher in LANA-expressing, as well as KSHV-infected, cells.
  • Furthermore, immunohistochemistry analyses revealed that survivin expression was upregulated in KSHV-associated Kaposi's sarcoma tissue, suggesting that LANA plays an important role in the upregulation of survivin expression in KSHV-infected endothelial cells.
  • Knockdown of survivin expression by lentivirus-delivered small hairpin RNA resulted in loss of cell proliferation in KSHV-infected cells.
  • Therefore, upregulation of survivin expression in KSHV-associated human cells contributes to their proliferation.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2000 Nov 2;10(21):1319-28 [11084331.001]
  • [Cites] J Virol. 2001 Jan;75(1):458-68 [11119614.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11177-82 [9556606.001]
  • [Cites] J Biol Chem. 2005 Aug 12;280(32):28867-76 [15951564.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2438-48 [16209919.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Trends Cell Biol. 2001 Feb;11(2):49-54 [11166196.001]
  • [Cites] J Hum Virol. 1997 Nov-Dec;1(1):19-29 [10195227.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9745-51 [15637054.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] Trends Mol Med. 2001 Dec;7(12):542-7 [11733216.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2613-22 [11965534.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10 [12042762.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):948-55 [12421830.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] J Virol. 2003 Jun;77(11):6188-96 [12743275.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Virol. 2003 Dec;77(23):12494-506 [14610173.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8568-80 [14634619.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] Mol Endocrinol. 2004 Feb;18(2):471-83 [14645499.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16822-31 [14742422.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):460-71 [15284899.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28113-21 [16861237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9 [16983096.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):609-15 [16934447.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2615-25 [17124180.001]
  • [Cites] Virology. 2007 Aug 1;364(2):317-29 [17434559.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2572-80 [17876054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16287-92 [17909182.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):5991-4 [17947459.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):61-70 [18075512.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):194-201 [17916908.001]
  • [Cites] Mol Cell. 2008 Apr 25;30(2):123-35 [18439892.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):983-93 [18570975.001]
  • [Cites] J Virol. 2005 Nov;79(22):14383-91 [16254372.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Gene. 1999 Oct 1;238(2):291-300 [10570957.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:305-11 [10567210.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1076-81 [10594755.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):417-22 [10662787.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • (PMID = 19439469.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / A167037; United States / NCI NIH HHS / CA / R01 CA091792; United States / NCI NIH HHS / CA / K99 CA126182-02; United States / NCI NIH HHS / CA / CA091792; United States / NIDCR NIH HHS / DE / DE017338; United States / NCI NIH HHS / CA / K99 CA126182; United States / NCI NIH HHS / CA / R00 CA126182; United States / NCI NIH HHS / CA / CA126182-03; United States / NCI NIH HHS / CA / CA126182-02; United States / NIDCR NIH HHS / DE / R01 DE017338; United States / NCI NIH HHS / CA / R00 CA126182-03; United States / NCI NIH HHS / CA / K99CA126182; United States / NCI NIH HHS / CA / CA072510
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Nuclear Proteins; 0 / Sp1 Transcription Factor; 0 / Tumor Suppressor Protein p53; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ PMC2704763
  •  go-up   go-down


71. Alderson GL, Jones AC, McGuff HS, Tiner BD: Oral and maxillofacial pathology case of the month. Malignant lymphoma, diffuse large B cell type. Tex Dent J; 2006 Mar;123(3):300, 304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral and maxillofacial pathology case of the month. Malignant lymphoma, diffuse large B cell type.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625961.001).
  • [ISSN] 0040-4284
  • [Journal-full-title] Texas dental journal
  • [ISO-abbreviation] Tex Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO: Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol; 2005 Apr;16(4):618-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in mantle cell lymphoma.
  • BACKGROUND: Patients with mantle cell lymphoma (MCL) have in general, lower response rates and overall survival (OS) than those with other B-cell non-Hodgkin's lymphomas.
  • The role of hematopoietic stem cell transplantation (HSCT) in MCL is unclear.
  • Hence we decided to study the clinical course of patients who received autologous and allogeneic HSCT for MCL.
  • METHODS: Ninety-seven patients, (80 patients-autologous; 17 patients-allogeneic) who received a HSCT for mantle cell lymphoma were included in the study.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781489.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Pitman SD, Huang Q, Zuppan CW, Rowsell EH, Cao JD, Berdeja JG, Weiss LM, Wang J: Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol; 2006 Apr;30(4):470-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
  • Although Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder (HL-like PTLD) has been grouped with classic Hodgkin lymphoma type PTLD (HL-PTLD), controversy remains as to whether it is truly a form of HL or whether it should be more appropriately classified as a form of B-cell PTLD.
  • Because only few cases of HL-like PTLD have been reported, their pathologic nature and clinical behavior have not been well defined.
  • This report characterized 5 cases of HL-like PTLD with respect to their immunophenotype, EBV status, clonality, and clinical outcome.
  • All of the patients were male, with ages ranging from 1.5 to 55 years at diagnosis.
  • All were EBV-related (EBER+) with the large neoplastic cells CD20/CD79a positive but CD15 negative.
  • All patients were managed by initial reduction/withdrawal of immunosuppression, with 2 also receiving chemotherapy for non-HL.
  • Three patients died of progressive disease within 2 to 3 months after diagnosis, 1 is alive and well 2 years later, and the fifth was disease free but died of unrelated causes (graft coronary disease) 2 years later.
  • We conclude that, although HL-like PTLD morphologically simulates classic HL PTLD, there are important immunophenotypic, molecular genetic, and clinical differences, suggesting it is in fact most often a B-cell PTLD.
  • Distinction between HL and HL-like PTLD may be important for clinical management and prognosis.
  • [MeSH-major] B-Lymphocytes / pathology. Hodgkin Disease / etiology. Hodgkin Disease / pathology. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / pathology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Child. Clone Cells. DNA, Neoplasm / analysis. Diagnosis, Differential. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / pathology. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunocompromised Host. Immunosuppression. Infant. Male. Middle Aged. Postoperative Complications. RNA, Viral / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625093.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


74. Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, Pérez-Seoane C, Domínguez P, Camacho FI, Piris MA: Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol; 2008 Dec;32(12):1787-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with follicular T-cell markers.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) in western countries are uncommon tumors with unfavorable prognosis.
  • They may be subclassified as anaplastic large-cell lymphomas (ALCLs), angioimmunoblastic-T-cell lymphomas (AITLs), or unspecified peripheral T-cell lymphomas (PTCLs-U).
  • It has recently been demonstrated that AITLs originate from germinal center follicular helper T cells (TFH), whereas the normal counterparts of other PTCLs remain essentially unknown.
  • The aim of this study was to establish whether other PTCL subgroups also express TFH cell markers.
  • PD-1-positive cases, which did not fulfill all the criteria for AITL, were further evaluated in whole-tissue sections for another 12 immunohistochemical markers, including the TFH cell markers CXCL13, CD10, and BCL6.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • Morphologic, clinical, and follow-up data were reviewed.
  • RESULTS: Twenty-five out of 87 non-AITL cases (28.75%) showed PD-1 immunostaining.
  • All cases expressed at least 2 TFH cell markers.
  • Of the remainder, 1 was considered to be early AITL, 1 was diagnosed as ALCL-anaplastic lymphoma kinase-negative, and 4 of the other 6 PTCLs-U had morphology consistent with lymphoepithelioid (Lennert's) lymphoma.
  • Our series of patients did not differ significantly in their clinical presentation from most reported PTCL cases in the literature: 55% of them were alive and 35% were in complete remission after a median follow-up of 15 months after cyclophosphamide, dexorubicin, vincristine, and prednisone-based chemotherapy.
  • CONCLUSIONS: TFH cell markers, especially PD-1, were expressed in a subset of PTCLs not classified as AITL, although most of them shared some morphologic features with AITL.
  • This suggests that the spectrum of AITL may be wider than previously thought, possibly including cases of lymphoepithelioid (Lennert's) lymphoma.
  • Additionally, the results suggest that a subgroup of PTCLs-U, distinct from AITL and including some cases denominated as ALCL, may also be derived from TFH cells, although they develop along a distinct pathogenic pathway.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers / analysis. Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemokine CXCL13 / biosynthesis. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / biosynthesis. Programmed Cell Death 1 Receptor. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. T-Lymphocytes, Helper-Inducer / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779728.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCOR protein, human; 0 / Biomarkers; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


75. Rifkind J, Mollee P, Messner HA, Lipton JH: Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look? Leuk Lymphoma; 2005 Feb;46(2):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?
  • Mantle cell lymphoma is a subtype of non-Hodgkin's lymphoma.
  • Mantle cell is generally considered incurable with a median overall survival of about 3 years.
  • Autologous stem cell transplantation does not appear to improve survival with most patients relapsing after transplant and no disease-free plateau.
  • We present 6 mantle cell patients that had a mean of 3 different types of therapy prior to allogeneic transplantation.
  • Survival from the date of diagnosis is a median of 6.5 plus years.
  • The results of this series would suggest that in a selected group of patients allogeneic stem cell transplantation may be the treatment of choice for lymphomas not curable by standard therapy or autotransplant.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Mantle-Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Graft Survival. Graft vs Host Disease / drug therapy. Humans. Male. Middle Aged. Remission Induction / methods. Retrospective Studies. Survival Rate. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621804.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Hersey P: Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol; 2006 Mar;18(2):189-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite a range of different biochemical targets, most agents kill cancer cells by induction of apoptosis.
  • RECENT FINDINGS: Investigation of this process has provided insights into the resistance mechanisms in cancer cells and to development of a range of new agents that target apoptosis pathways.
  • These include agents which inhibit antiapoptotic B cell lymphoma-2 family proteins and inhibitor of apoptosis proteins.
  • These early trials show much promise and suggest this approach to development of new therapies will lead to much needed advances in treatment of this disease.
  • [MeSH-minor] Drug Resistance, Neoplasm / drug effects. Enzyme Inhibitors / therapeutic use. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / physiopathology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Signal Transduction / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology. X-Linked Inhibitor of Apoptosis Protein / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462190.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Enzyme Inhibitors; 0 / X-Linked Inhibitor of Apoptosis Protein; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Number-of-references] 85
  •  go-up   go-down


77. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F: Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol; 2006 Sep;17(9):1434-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy.
  • BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) has been correlated to hepatitis C virus (HCV) infection in few series, but characteristics and outcome of these patients remain undefined.
  • RESULTS: Median age at presentation was 63 years and 8% of patients had DLBCL transformed from low-grade lymphomas.
  • CONCLUSIONS: Patients with HCV-positive DLBCL share distinctive clinical features.
  • Future studies should prospectively evaluate the association between HCV and aggressive lymphomas.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766591.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


78. Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR: Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood; 2007 Apr 15;109(8):3409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.
  • Standard chemotherapy fails in 40% to 50% of patients with diffuse large B-cell lymphoma (DLBCL).
  • Some of these failures can be salvaged with high-dose regimens, suggesting a role for drug resistance in this disease.
  • Among genes in the GSH family, glutathione peroxidase 1 (GPX1) had the most significant adverse effect on disease-specific overall survival (dOS) in the primary dataset (n = 130) (HR: 1.68; 95% CI: 1.26-2.22; P < .001).
  • This effect remained statistically significant after controlling for biologic signature, LLMPP cell-of-origin signature, and IPI score, and was confirmed in the validation dataset (n = 39) (HR: 1.7; 95% CI: 1.05-2.8; P = .033).
  • Recursive partitioning identified a group of patients with low-level expression of GPX1 and multidrug resistance 1 (MDR1; ABCB1) without early treatment failures and with superior dOS (P < .001).
  • Overall, our findings suggest an important association of oxidative-stress defense and drug elimination with treatment failure in DLBCL and identify GPX1 and ABCB1 as potentially powerful biomarkers of early failure and disease-specific survival.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):141-6 [8425524.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1222-7 [16956821.001]
  • [Cites] Cell. 1993 Oct 22;75(2):241-51 [7503812.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(1):67-71 [7513621.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4313-20 [8044778.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6215-20 [7954469.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2453-9 [7964963.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Immunol. 1996 Apr 15;156(8):2792-800 [8609398.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):967-78 [8763337.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):300-5 [9305847.001]
  • [Cites] J Cell Biochem. 1999 May 1;73(2):259-77 [10227389.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 25;5:159 [15504239.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7934-40 [15585627.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):643-53 [10690550.001]
  • [Cites] J Intern Med. 2000 May;247(5):521-34 [10809991.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):480-7 [10900222.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3417-23 [10999723.001]
  • [Cites] Free Radic Biol Med. 2000 Aug;29(3-4):323-33 [11035261.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):12749-55 [11278289.001]
  • [Cites] Mol Pharmacol. 2001 Sep;60(3):488-96 [11502879.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):405-12 [11934739.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):214-20 [11994742.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30792-7 [12077134.001]
  • [Cites] Toxicol Sci. 2002 Oct;69(2):383-90 [12377987.001]
  • [Cites] Leukemia. 2003 May;17(5):972-7 [12750712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7369-75 [14576844.001]
  • [Cites] Physiol Genomics. 2004 Feb 13;16(3):361-70 [14645736.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1862-8 [14615382.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):25535-43 [15054096.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):413-8 [15254739.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):e124 [15333675.001]
  • [Cites] Cancer. 1978 Oct;42(4):1705-10 [361209.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):347-50 [3567087.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3844-8 [2544260.001]
  • [Cites] Biochem J. 1990 Jun 1;268(2):309-15 [2194447.001]
  • [Cites] Biochem Pharmacol. 1990 Oct 15;40(8):1833-42 [2242017.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):521-7 [1845955.001]
  • [Cites] Oncology. 2005;68(4-6):422-31 [16020972.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3594-601 [16081686.001]
  • [Cites] Leuk Res. 1993 Feb;17(2):149-56 [8094105.001]
  • (PMID = 17179223.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA076931; United States / NCI NIH HHS / CA / 5K12 CA 076931
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / Membrane Transport Proteins; 0 / Organic Anion Transporters; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / glutathione transporter; EC 1.11.1.- / glutathione peroxidase GPX1; EC 1.11.1.9 / Glutathione Peroxidase
  • [Other-IDs] NLM/ PMC1852238
  •  go-up   go-down


79. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal IS: Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol; 2006 Aug;148(8):1116-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
  • 1. Cell-surface expression of CD40 in B-cell malignancies and multiple solid tumors has raised interest in its potential use as a target for antibody-based cancer therapy.
  • SGN-40, a humanized monoclonal anti-CD40 antibody, mediates antibody-dependent cytotoxicity and inhibits B-cell tumor growth in vitro, properties of interest for the treatment of cancers, and is currently in Phase I clinical trials for B-cell malignancies.
  • 2. Effect of SGN-40 in xenograft model of CD40-expressing B-cell lymphoma in severe-combined immune deficiency mice and its in vivo pharmacokinetics properties in normal mice, rats and cynomolgus monkeys were studied.
  • 3. Treatment with SGN-40 significantly increased the survival of mice xenografted with human B-cell lymphoma cell line.
  • These data suggest that SGN-40 has appropriate pharmacokinetic properties that support its clinical use.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2002 Sep-Oct;88(5):361-6 [12487551.001]
  • [Cites] Exp Cell Res. 2002 Nov 1;280(2):201-11 [12413886.001]
  • [Cites] Br J Haematol. 2003 May;121(4):592-6 [12752100.001]
  • [Cites] Nat Rev Immunol. 2003 Sep;3(9):745-56 [12949498.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2846-52 [15087402.001]
  • [Cites] Nat Med. 2004 May;10(5):540-4 [15107845.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):360-7 [15251129.001]
  • [Cites] EMBO J. 1989 May;8(5):1403-10 [2475341.001]
  • [Cites] Xenobiotica. 1990 Nov;20(11):1201-31 [2275215.001]
  • [Cites] Blood. 1994 May 15;83(10):2787-94 [7514045.001]
  • [Cites] Annu Rev Immunol. 1994;12:881-922 [7516669.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2597-603 [7522634.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):159-67 [8551219.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] Br J Haematol. 1997 May;97(2):409-17 [9163608.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1927-33 [9292526.001]
  • [Cites] Annu Rev Immunol. 1998;16:111-35 [9597126.001]
  • [Cites] Breast Cancer Res Treat. 1998 Jul;50(1):27-36 [9802617.001]
  • [Cites] Immunol Today. 1998 Nov;19(11):502-6 [9818543.001]
  • [Cites] Blood. 1999 May 1;93(9):2999-3007 [10216096.001]
  • [Cites] Lancet. 1999 Oct 9;354(9186):1225-7 [10520628.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]
  • [Cites] Cancer Gene Ther. 2003 Jan;10(1):1-13 [12489023.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):2-17 [10647992.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3225-31 [10866315.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5503-15 [10891490.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3280-7 [11432896.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7556-62 [11606394.001]
  • [Cites] Blood. 2002 Jul 1;100(1):217-23 [12070030.001]
  • [ErratumIn] Br J Pharmacol. 2007 Jan;150(2):248
  • (PMID = 16847437.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD40
  • [Other-IDs] NLM/ PMC1752010
  •  go-up   go-down


80. Beverly LJ, Varmus HE: MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene; 2009 Mar 5;28(9):1274-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family.
  • Signals that control the fine balance between cell death and cell survival are altered during tumorigenesis.
  • Understanding the mechanisms by which this balance is perturbed, leading to excessive cell survival, is important for designing effective therapies.
  • Proteins belonging to the B-cell lymphoma (BCL) family are known to regulate death responses to apoptotic signals, especially those originating within cells.
  • A subset of BCL family members capable of inhibiting cell death is known to contribute to tumorigenesis; however, it is not known whether all six antiapoptotic BCL family members play a causal role in tumor development.
  • In addition, high levels of each family member are found in either solid human tumors or cell lines derived from human leukemias or lymphomas.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 May 7;274(19):13298-304 [10224090.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1684-97 [18339423.001]
  • [Cites] J Exp Med. 2005 Feb 21;201(4):603-14 [15728238.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2452-61 [15972450.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jul;3(7):388-98 [16826219.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1403-10 [14973057.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6684-91 [15153484.001]
  • [Cites] Gene. 2004 May 26;333:71-9 [15177682.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):241-9 [15380515.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Curr Biol. 1997 Dec 1;7(12):913-20 [9382837.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5857-64 [9600884.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1701s-1706s [10197583.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):375-88 [17097560.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):782-91 [17234790.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):405-13 [17377525.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1070-7 [17459056.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1763-72 [17554384.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]
  • [Cites] Bioinformatics. 2007 Nov 1;23(21):2947-8 [17846036.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3268-77 [18519752.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • (PMID = 19137012.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094060-06A10001; United States / NCI NIH HHS / CA / P01 CA094060; United States / NCI NIH HHS / CA / 2P01 CA094060-06A1; United States / NCI NIH HHS / CA / P01 CA094060-06A10001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS99926; NLM/ PMC2743088
  •  go-up   go-down


81. Isogai R, Fukao M, Kawada A: Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. J Dermatol; 2007 Aug;34(8):556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a malignant lymphoma with a relatively good prognosis, consisting of CD30-positive, undifferentiated, large cells.
  • In conclusion, the VNCOP-B regimen might be an effective treatment for elderly patients with good performance status, CHOP-resistant patients or patients with aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy


82. Yepes JF, Mozaffari E, Ruprecht A: Case report: B-cell lymphoma of the maxillary sinus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Dec;102(6):792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: B-cell lymphoma of the maxillary sinus.
  • The radiographic manifestation of malignant lesions of the maxillary sinus on dental radiographs may be nonspecific, making it difficult to differentiate the lesion from disease of odontogenic origin or more benign sinus pathoses.
  • A radiopaque mass in the maxillary sinus, resulting from a malignant neoplasm growing within or extending into the sinus, can be easily confused with the mass of a mucous retention pseudocyst.
  • Similarly, a malignant growth in the early stages of development can produce radiographic patterns in the alveolar process that may resemble inflammation of odontogenic origin.
  • A case of B-cell lymphoma is reported.
  • Radiographic and clinical features that should be considered in establishing a differential diagnosis of malignant disease are discussed.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Maxillary Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Mucocele / diagnosis. Radiography, Panoramic. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138183.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Wei J, Kitada S, Stebbins JL, Placzek W, Zhai D, Wu B, Rega MF, Zhang Z, Cellitti J, Yang L, Dahl R, Reed JC, Pellecchia M: Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem; 2010 Nov 25;53(22):8000-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
  • Overexpression of antiapoptotic Bcl-2 family proteins is commonly related with tumor maintenance, progression, and chemoresistance.
  • Guided by nuclear magnetic resonance (NMR) binding assays, a series of 5,5' substituted compound 6a (Apogossypolone) derivatives was synthesized and identified pan-active antagonists of antiapoptotic Bcl-2 family proteins, with binding potency in the low micromolar to nanomolar range.
  • Compound 6f inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, and Mcl-1 with IC(50) values of 3.10, 3.12, and 2.05 μM, respectively.
  • In a cellular assay, 6f potently inhibits cell growth in several human cancer cell lines in a dose-dependent manner.

  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. Gossypol .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Eur J Med Chem. 2000 Sep;35(9):805-13 [11006482.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7133-41 [11156422.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):173-82 [11175750.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Nat Rev Drug Discov. 2002 Feb;1(2):111-21 [12120092.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] J Med Chem. 1991 Oct;34(10):2954-61 [1920349.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] J Med Chem. 1995 Jun 23;38(13):2427-32 [7608907.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29897-902 [8939932.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] Adv Pharmacol. 1997;41:501-32 [9204157.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):3-13 [9685174.001]
  • [Cites] Cancer Lett. 2009 Jan 8;273(1):107-13 [18782651.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):92-8 [19236755.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):904-13 [19372563.001]
  • [Cites] Oncol Rep. 2009 Jul;22(1):193-8 [19513523.001]
  • [Cites] J Med Chem. 2009 Jul 23;52(14):4511-23 [19555126.001]
  • [Cites] J Med Chem. 2010 May 27;53(10):4166-76 [20443627.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cell. 1999 Jan 22;96(2):245-54 [9988219.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):171-80 [10096426.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):5-6 [16023593.001]
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6 [16859853.001]
  • [Cites] Org Lett. 2006 Dec 21;8(26):5919-22 [17165894.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):641-62 [17256834.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):970-81 [16909112.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1046-53 [17363497.001]
  • [Cites] Bioorg Chem. 2007 Aug;35(4):344-53 [17512966.001]
  • [Cites] J Med Chem. 2007 Jul 12;50(14):3163-6 [17552510.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5828-32 [17353899.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34 [17505826.001]
  • [Cites] Mol Cancer. 2008;7:20 [18275607.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3211-9 [18202226.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2192-202 [18645028.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2418-29 [18712728.001]
  • [Cites] Acta Pharmacol Sin. 2008 Dec;29(12):1467-77 [19026166.001]
  • (PMID = 21033669.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA149668-01; United States / NCI NIH HHS / CA / CA113318; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / U19 CA113318-04; United States / NCI NIH HHS / CA / CA113318-04; United States / NCI NIH HHS / CA / R01 CA149668-01; United States / NCI NIH HHS / CA / R01 CA149668; United States / NCI NIH HHS / CA / CA149668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 6,6',7,7'-tetrahydroxy-3,3'-dimethyl-5,5'-bis(4-methylphenethyl)-2,2'-binaphthyl-1,1',4,4'-tetraone; 0 / Antineoplastic Agents; 0 / Bax protein (53-86); 0 / Naphthoquinones; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypolone; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS249613; NLM/ PMC3059195
  •  go-up   go-down


84. You Y, Xia LH, Zhang C, Liu F, Chen ZC, Zou P: [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases]. Zhonghua Yi Xue Za Zhi; 2007 Nov 27;87(44):3127-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases].
  • OBJECTIVE: To investigate the clinical effect of peripheral blood progenitor (PBPC) selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma (NHL) patients.
  • METHODS: Peripheral blood was collected from 5 NHL patients, 3 males and 2 females, aged 29 (14 - 58), t3 with T cell NHL, 1 with diffused large B cell NHL and 1 with genuine histiocytic lymphoma, 2 at the IIA stage and 3 at the IVB stage, and 4 in their first complete remission (CR1) period, and 1 in partial remission (PR2).
  • CD34(+) cells were collected by magnetic-activated cell sorting system, enriched, and re-infused after pretreatment with chemotherapy and granulocyte-colony stimulating factor.
  • RESULTS: Magnetic-activated cell sorting resulted in 3.3 log depletion of CD34(-) cells and a median yield of CD34(+) selected cells was reinfused with the dose of 2.0 x 10(6)/kg.
  • CONCLUSION: Brings prompt and stable engraftment, autologous selected PBPC CD34(+) cells transplantation may safely improve the clinical outcome of the patients with NHL.
  • [MeSH-major] Antigens, CD34 / blood. Lymphoma, Non-Hodgkin / surgery. Peripheral Blood Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269872.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


85. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K: Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol; 2007 Jun;82(6):446-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
  • Nongastric marginal zone B-cell lymphoma (NG-MZL) is a relatively uncommon indolent lymphoma.
  • Ann Arbor stage I/II disease was present in 78% (167 out of 215).
  • Eighty percent (172/215) were in low risk group according to Follicular Lymphoma International Prognostic Index (FLIPI).
  • NG-MZL is an indolent disease.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17266060.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, Botto B, Ciccone G, Gaidano G, Falchi L, Freilone R, Novero D, Orsucci L, Pavone V, Pogliani E, Rota-Scalabrini D, Salvi F, Tonso A, Tucci A, Levis A, Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL): Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica; 2009 Sep;94(9):1250-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
  • BACKGROUND: We investigated the addition of rituximab to dose-dense and high-dose chemotherapy with autologous stem cell transplantation in patients with untreated poor-prognosis diffuse large B-cell lymphoma.
  • DESIGN AND METHODS: Ninety-four young patients (age, 18-60) with stage III-IV diffuse large B-cell lymphoma at intermediate/high or high risk according to the age-adjusted International Prognostic Index were enrolled into a phase II trial.
  • The treatment was as follows: four courses of bi-weekly rituximab-cyclophosphamide-epirubicin-vincristine-prednisone (R-MegaCEOP14), two courses of rituximab-mitoxantrone-cytarabine-dexamethasone (R-MAD) and carmustine-etoposide-cytarabine-melphalan (BEAM) with autologous stem cell transplantation.
  • This historical group was treated with eight weekly infusions of methotrexate-doxorubicin-cyclophosphamide-vincristine-prednisone-bleomycin (MACOP-B), two courses of MAD and BEAM with autologous stem cell transplantation.
  • CONCLUSIONS: These results suggest that the addition of rituximab to high-dose chemotherapy is effective and safe in diffuse large B-cell lymphoma with a poor-prognosis and such regimens need to be compared to dose-dense chemoimmunotherapy without autologous stem cell transplantation in randomized trials.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Male. Middle Aged. Rituximab. Survival Rate. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1802-11 [17554382.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5509-14 [18445689.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3166-75 [18490650.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3425-33 [18544678.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4413-9 [12431962.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1255-62 [12663712.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(2):139-43 [12838277.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1304-15 [14607760.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):491-8 [9053470.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4561-6 [15542807.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] Haematologica. 2005 Jun;90(6):793-801 [15951292.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):541-7 [16019482.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Haematologica. 2006 Apr;91(4):496-502 [16537117.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3058-64 [16384932.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4623-7 [16467197.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Bone Marrow Transplant. 2007 May;39(9):523-7 [17369863.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):338-46 [17400393.001]
  • [Cites] Haematologica. 2007 Jun;92(6):778-83 [17550850.001]
  • [Cites] Blood. 2008 Jan 15;111(2):537-43 [17971487.001]
  • (PMID = 19586937.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2738717
  •  go-up   go-down


87. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM: Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant; 2009 May;15(5):547-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
  • Patients with chemorefractory aggressive non-Hodgkin's lymphomas (NHL) generally have poor clinical outcomes with available therapies.
  • We examined allogeneic transplantation outcomes for 46 patients with chemorefractory, aggressive NHL patients who had either stable disease (SD; n = 32) or progressive disease (PD; n = 14), respectively, following last salvage treatment.
  • Diagnoses included diffuse large B-cell lymphoma (n = 18), Burkitt's lymphoma (n = 3), transformed B cell lymphoma (n = 5), mantle cell lymphoma (n = 11), and peripheral T cell lymphoma (n = 9).
  • The rate of grade II-IV acute graft-versus-host disease (aGVHD) was 43%.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Disease Progression. Follow-Up Studies. Graft vs Host Disease. Humans. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult


88. Slater DN: The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol; 2005 Nov;153(5):874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.
  • Following consensus meetings of the two parent organizations, a new World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for primary cutaneous lymphomas has recently been published.
  • The new classification will facilitate more uniformity in diagnosis, management and treatment of cutaneous lymphomas.
  • In particular, it provides a useful distinction between indolent and more aggressive types of primary cutaneous lymphoma and provides practical advice on preferred management and treatment regimens.
  • This will thereby prevent patients receiving high-grade treatment for low-grade biological disease.
  • In cutaneous T-cell lymphomas, these include folliculotropic mycosis fungoides, defining features of Sézary syndrome, primary cutaneous CD30+ lymphoproliferative disorders (primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis and borderline lesions) and subcutaneous panniculitis-like T-cell lymphoma.
  • Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma and cutaneous gamma/delta T-cell lymphoma are allocated provisional entry status and thereby afford better definitions for some cases of currently unspecified primary cutaneous peripheral T-cell lymphoma.
  • In cutaneous B-cell lymphomas, diseases which have found new consensus agreement include primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicular centre lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type and primary cutaneous diffuse large B-cell lymphoma, other.
  • CD4+/CD56+ haematodermic neoplasm (early plasmacytoid dendritic cell leukaemia/lymphoma) now appears as a precursor haematological neoplasm and replaces the previous terminology of blastic NK-cell lymphoma.
  • Other haematopoietic and lymphoid tumours involving the skin, as part of systemic disease, will appear in the forthcoming WHO publication Tumours of the Skin.
  • The new classification raises interesting new problems and questions about primary cutaneous lymphoma and some of these are discussed in this article.
  • It is, however, a splendid signpost indicating the direction in which research in cutaneous lymphoma needs to go.
  • [MeSH-major] Lymphoma / classification. Skin Neoplasms / classification
  • [MeSH-minor] Humans. Killer Cells, Natural. Lymphoma, B-Cell / classification. Lymphoma, T-Cell, Cutaneous / classification. Mycosis Fungoides / classification. Sezary Syndrome / classification. World Health Organization

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225594.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


89. Coupland SE, Loddenkemper C, Smith JR, Braziel RM, Charlotte F, Anagnostopoulos I, Stein H: Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma. Invest Ophthalmol Vis Sci; 2005 Nov;46(11):3957-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
  • PURPOSE: Several B-cell-associated transcription factors and their coactivators, including BCL-6, BSAP/PAX5, BOB.1/OBF.1, Oct.2, MUM1/IRF4, and PU.1, have been detected in peripheral B-cell lymphomas.
  • There are limited data on their expression in centrally located lymphoid neoplasms, such as primary intraocular lymphoma (PIOL) or primary central nervous system lymphoma (PCNSL).
  • PIOL is a rare non-Hodgkin lymphoma, considered a subtype of PCNSL.
  • Both are usually diffuse, large B-cell lymphoma (DLBCL), rarely manifest outside the CNS, and carry a poor prognosis.
  • Aberrant coexpression of MUM1/IRF4, PAX5, MUM1/IRF4, and BCL-6 was observed in most PIOLs/PCNSLs.
  • CONCLUSIONS: These data provide further support to the notion that peripheral and centrally located DLBCLs differ in clinical, immunophenotypic, and genotypic features, despite their similar morphologic characteristics.
  • PIOL and PCNSL tumor cells are most likely to be derived from mature B-cells that have undergone the germinal center reaction.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Eye Neoplasms / metabolism. Immunoglobulin Heavy Chains / metabolism. Immunoglobulin Light Chains / metabolism. Lymphoma, B-Cell / metabolism. Octamer Transcription Factor-2 / metabolism
  • [MeSH-minor] B-Cell-Specific Activator Protein / metabolism. Genotype. Humans. Immunoenzyme Techniques. Immunophenotyping. Interferon Regulatory Factors / metabolism. Organic Cation Transport Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Retrospective Studies. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249468.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / R01 EY14909
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / Interferon Regulatory Factors; 0 / Octamer Transcription Factor-2; 0 / Organic Cation Transport Proteins; 0 / PAX5 protein, human; 0 / POU2AF1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / interferon regulatory factor-4; 0 / proto-oncogene protein Spi-1
  •  go-up   go-down


90. Ochiai H, Kawano H, Miyaoka R, Kawano N, Shimao Y, Kawasaki K: Primary diffuse large B-cell lymphomas of the temporoparietal dura mater and scalp without intervening skull bone invasion. Neurol Med Chir (Tokyo); 2010;50(7):595-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphomas of the temporoparietal dura mater and scalp without intervening skull bone invasion.
  • A 72-year-old man presented with an extremely rare case of primary diffuse large B-cell lymphomas (DLBCLs) of the dura and scalp existing independently without intervening cranial vault invasion.
  • The present case of DLBCLs in the scalp and dura without intervening skull bone invasion indicates that malignant lymphoma should be considered in the differential diagnosis of scalp and dural tumors without intervening skull bone invasion.
  • [MeSH-major] Dura Mater / surgery. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Scalp / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Humans. Male. Neoplasm Invasiveness. Parietal Bone. Radiotherapy, Adjuvant. Temporal Bone


91. Talaulikar D, Choudhury A, Shadbolt B, Brown M: Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma; 2008 May;49(5):959-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas.
  • Recently, it has been reported to be associated with poor outcome in diffuse large B-cell lymphoma (DLBCL).
  • The aim of this study was to determine the incidence of lymphocytopenia at diagnosis in patients with DLBCL, and to confirm its significance as a prognostic factor, particularly in relation to the international prognostic index (IPI).
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphopenia

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 May;49(5):843-4 [18464103.001]
  • (PMID = 18464115.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


92. Visani G, Isidori A: Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Rev Anticancer Ther; 2009 Mar;9(3):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
  • Anthracyclines, including doxorubicin, are widely used in the treatment of B-cell non-Hodgkin's lymphoma (NHL).
  • However, their clinical potential is limited by their cardiotoxic adverse effects, which include cardiomyopathy and congestive heart failure.
  • Nonpegylated liposomal doxorubicin produced a promising response rate when substituted for conventional doxorubicin in the cyclophosphamide, doxorubicin, vincristine and prednisolone regimen in the treatment of patients with NHL either at diagnosis or at relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Humans. Liposomes. Lymphoma, AIDS-Related / drug therapy. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275512.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  • [Number-of-references] 31
  •  go-up   go-down


93. Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P: Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant; 2008 Jan;27(1):100-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
  • BACKGROUND: Post-transplant lymphoproliferative disease (PTLD) is a severe complication in transplant recipients.
  • Six patients developed a EBV-associated B-cell lymphoma (PTLD), among whom 4 (67%) were receiving CsA-azathioprine.

  • Genetic Alliance. consumer health - Heart Disease.
  • Genetic Alliance. consumer health - Heart Transplant.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187094.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunosuppressive Agents
  •  go-up   go-down


94. Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D, Koeffler HP: Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk Res; 2007 Apr;31(4):523-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines.
  • S.B inhibited the growth of ALL, lymphoma and myeloma cell lines by inducing apoptosis and cell cycle arrest at clinically achievable concentrations.
  • The anti-proliferative effect was associated with mitochondrial damage, modulation of the Bcl family of genes, increased level of the CDK inhibitor p27(KIP1) and decreased level of c-myc oncogene.
  • Thus, Scutellaria baicalensis should be tested in clinical trials for these hematopoietic malignancies.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Drugs, Chinese Herbal / therapeutic use. Multiple Myeloma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Scutellaria baicalensis / chemistry
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Colony-Forming Units Assay. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Drug Screening Assays, Antitumor. Flavonoids / therapeutic use. Flow Cytometry. Humans. Membrane Potential, Mitochondrial / drug effects. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007926.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Flavonoids; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 347Q89U4M5 / baicalin
  •  go-up   go-down


95. Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R, Dutch Cutaneous Lymphoma Group: Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol; 2007 Dec;143(12):1520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
  • OBJECTIVE: To evaluate the results of radiotherapy in patients with primary cutaneous B-cell lymphoma (CBCL) classified according to the criteria of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification.
  • SETTING: Eight dermatology departments collaborating in the Dutch Cutaneous Lymphoma Group.
  • These cases were classified according to the WHO-EORTC classification and consisted of 25 primary cutaneous marginal zone lymphomas (PCMZLs), 101 primary cutaneous follicle center lymphomas (PCFCLs), and 27 primary cutaneous large B-cell lymphomas, leg type (PCLBCLs, LT).
  • MAIN OUTCOME MEASURES: Complete remission rate, relapse rate, 5-year relapse-free survival, 5-year overall survival, and 5-year disease-specific survival.
  • Relapse rates for PCMZL, PCFCL, and PCLBCL, LT were 60%, 29%, and 64%, and the 5-year disease-specific survival was 95%, 97%, and 59%, respectively.
  • The PCFCLs presenting on the legs had a higher relapse rate (63%) and a much lower 5-year disease-specific survival (44%) than PCFCLs at other sites (relapse rate, 25%; 5-year disease-specific survival, 99%).
  • However, patients with PCFCL presenting with lesions on the leg and patients with PCLBCL, LT display a more unfavorable clinical course and should therefore be treated with more aggressive treatment modalities.
  • [MeSH-major] Lymphoma, B-Cell / classification. Lymphoma, B-Cell / radiotherapy. Skin Neoplasms / classification. Skin Neoplasms / radiotherapy. World Health Organization
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Incidence. Lymphoma / classification. Lymphoma / radiotherapy. Lymphoma, Follicular / classification. Lymphoma, Follicular / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Remission Induction. Retrospective Studies. Survival Analysis


96. Pantazis G, Psaras T, Krope K, von Coelln R, Fend F, Bock T, Schittenhelm J, Melms A, Meyermann R, Bornemann A: Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high IgG levels in the cerebrospinal fluid as a diagnostic clue. Clin Neuropathol; 2010 Nov-Dec;29(6):378-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high IgG levels in the cerebrospinal fluid as a diagnostic clue.
  • Herein, we report the case of a 72-year-old male with an exceedingly rare manifestation of a low-grade lymphoma in the brain associated with light chain deposition disease (LCDD).
  • Histopathology revealed a low grade lymphoplasmacytic B-cell lymphoma with light chain deposition disease (LCDD).
  • LCDD exclusively affecting the brain is an exceedingly rare finding.
  • It can be associated with low-grade B-cell lymphoma.
  • Compared with the two younger patients previously reported, the course of the disease was of a slow-evolving nature.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Diseases / immunology. Brain Neoplasms / diagnosis. Immunoglobulin G / cerebrospinal fluid. Immunoglobulin Light Chains / metabolism. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21073842.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


97. Jacobs SA, Foon KA: The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opin Biol Ther; 2007 Nov;7(11):1749-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.
  • The role of rituximab in the treatment of B-cell lymphomas has rapidly emerged from the relapsed setting to first-line combination regimens across the broad range of histologic subtypes.
  • The role of maintenance rituximab in indolent lymphomas after first-line therapy needs to be defined along with the integration of radioimmunotherapy into the first-line therapeutic regimens.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic. Humans. Rituximab

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961097.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 112
  •  go-up   go-down


98. Kurkus J, Nilsson R, Lindén O, Schönström N, Sandberg BE, Tennvall J: Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood. Artif Organs; 2007 Mar;31(3):208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of monoclonal antibodies (MAbs) in cytotoxic conjugates (radionuclides, toxins, or drugs) for targeting tumor cells is restricted due to toxicity in vital organs.
  • Through improved tumor targeting, it is possible to administer larger amounts of such labeled MAbs, thus improving the ability to eradicate tumor cells without increased normal organ toxicity.
  • During ECAT, excess radioimmunoconjugates, not bound to the tumor cells, can be removed improving tumor targeting.
  • Seven patients with B-cell lymphoma not responding to conventional treatment were studied.
  • The AA adsorbent had no effect on the blood cells, immunological status or P-bradykinin level.
  • [MeSH-major] Avidin / therapeutic use. Extracorporeal Circulation / instrumentation. Hemoperfusion / methods. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Sepharose / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343696.001).
  • [ISSN] 0160-564X
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / avidin-agarose; 1405-69-2 / Avidin; 9012-36-6 / Sepharose
  •  go-up   go-down


99. Campas-Moya C: Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc); 2009 Nov;45(11):787-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Romidepsin for the treatment of cutaneous T-cell lymphoma.
  • Romidepsin has shown promising anticancer effects in a wide variety of nonclinical cancer models both in vitro and in vivo by induction of apoptosis, cell differentiation and cell cycle arrest.
  • Romidepsin has been recently approved by the FDA for the treatment of cutaneous T-cell lymphoma (CTCL) patients who have received at least one prior systemic therapy.
  • It is currently under clinical investigation for the treatment of other hematological malignances and solid tumors as monotherapy and in combination with other anticancer agents.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Depsipeptides / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Evaluation, Preclinical. Drug Resistance, Neoplasm. Humans

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 20126671.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Depsipeptides; CX3T89XQBK / romidepsin
  • [Number-of-references] 59
  •  go-up   go-down


100. Jones K, Nourse J, Corbett G, Gandhi MK: Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Int J Lab Hematol; 2010 Feb;32(1 Pt 1):e169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
  • Histone deacytelase inhibitiors (HDACi) represent a new class of anti-lymphoma therapeutics.
  • Data in the clinical setting regarding on- and off-target effects of these agents are limited.
  • Epstein-Barr virus (EBV)-positive lymphomas represent a highly defined system in which to make these observations.
  • We present a case of a patient with multiple relapsed EBV-positive Diffuse Large B-cell Lymphoma that was chemo-refractory to anthracylcines, alkylating agents and rituximab.
  • Therapy resulted in detectable cell-free unencapsulated circulating EBV-DNA providing supportive evidence for the first-time that lysis of virus infected lymphoma cells is induced using this therapeutic combination.
  • EBV-specific CD8+ effector T-cell immunity was not impaired by VPA/GCV.
  • Although GCV/VPA was insufficient to induce clinical remission, our data furthers the rationale that more potent HDAC inhibitors such as butyrate or gemcitabine together with GCV, perhaps in combination with chemotherapy, should be further investigated as therapy in relapsed/refractory EBV-positive lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Epstein-Barr Virus Infections / drug therapy. Ganciclovir / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Valproic Acid / therapeutic use
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. T-Lymphocytes / virology

  • Hazardous Substances Data Bank. GANCICLOVIR .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196381.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Histone Deacetylase Inhibitors; 614OI1Z5WI / Valproic Acid; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down






Advertisement